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 Abstract 
Oligodeoxynucleotides (ODNs) containing electrophilic groups are useful in many 
studies including antisense drug development and DNA/protein interaction. Due to the use 
of strong nucleophiles for cleavage and deprotection, traditional ODN synthesis methods 
are not suitable for their preparation. To solve this problem, a new ODN synthesis 
technology using the 1,3-dithiane-2-yl-methoxycarbonyl (Dmoc) function as protecting 
groups and linker has been developed. Furthermore,  Dmoc-derivatives were developed to 
demonstrate the feasibility of the technology. The Dmoc and Dmoc derivative functions 
are stable under all ODN synthesis conditions using the phosphoramidite chemistry. Upon 
oxidation of the sulfides in them, because of the drastically increased acidity of H-2, the 
groups and linker are readily cleaved under nearly non-nucleophilic conditions. Many 
sensitive electrophiles were able to be incorporated on DNA strands successfully using 
these technologies. These include but are not limited to sensitive thioester, ethyl ester, alkyl 
chloride, and α-chloroacetamide moieties. 
1 
Chapter 1 Introduction 
1.1 Oligodeoxynucleotides (ODNs) 
Oligodeoxynucleotides (ODNs) are single-stranded deoxyribonucleic acids, also 
known as DNA, which consist of four nucleotides – deoxythymidine (dT), deoxycytidine 
(dC), deoxyadenosine (dA), and deoxyguanosine (dG). All four nucleotides contain their 
respective nucleobase, a 2’-deoxribose sugar moiety, and are linked together in a 3’ to 5’ 
fashion via a phosphate diester backbone. DNA is found in every known living organism, 
including many viruses, which provides pathways for genetic coding, cellular signaling, 
and reproduction.  
1.2 Applications of ODNs 
Synthetic ODNs hold a variety of applications in the pharmaceutical world such as 
antisense drug development, [1] synthetic biology, [2] CRISPR genome editing, [3] as well as 
DNA data storage. [4] Currently, several FDA approved oligonucleotide based antisense 
drugs are on the market such as fomivirsen, mipomersen, etelplirsen, and nisinersen.  
1.3 Solid Phase ODN Synthesis  
Generally, a universal solid support consisting of a controlled pore glass (CPG) 
covalently bonded to a succinyl linker is used in conjunction with phosphoramidite 
monomers to synthesize the desired ODN lengths (typically ranging from 15 - 100 
nucleotides). The synthetic DNA cycle consists of four different routine steps. Initially, the 
acid-labile 4,4-dimethoxytrityl protecting group (DMTr) on the 5’ alcohol end is removed 
by the treatment with 3% dichloroacetic acid in dichloromethane. This process is crucial 
2 
to unmask the primary alcohol functional group which enables the first coupling step to 
occur. The 5’-OH group is then reacted with a phosphoramidite monomer along with 
activator 1H-tetrazole. The activator is needed to catalyze and displace the diisisopropyl 
amino group of the newly added phosphoramidite monomer which creates an enhanced 
leaving group. A phosphite triester is generated once the 5’-OH group successfully reacts 
and displaces the activated leaving group. However, since the reaction yield is not 
quantitative the unreacted free 5’-OH groups on the resin-bound nucleotide, called failure 
sequences, need to be masked so they do not interfere with the rest of the synthetic cycle. 
This is generally achieved by capping them with an excess of acetic anhydride catalyzed 
by N-methyl imidazole. The fourth and final step of the cycle consists of the oxidation of 
the phosphite triester to its more stable pentavalent state. This is accomplished by the 
addition of iodine in the presence of water and pyridine. The resultant phosphotriester 
serves as the backbone of the DNA strand. After the desired ODN length is obtained it 
needs to be cleaved off the solid support. The exo-amino groups of the nucleotides are 
usually pre-protected with acetyl or benzoyl (for dA and dC) and isobutyryl (for dG) 
groups. The succinyl linker on the resin as well as these exo-amino protecting groups can 
easily be removed with concentrated ammonium hydroxide solution at 55 °C for 12 hours. 
Additionally, Ultramild conditions have also been developed. In these cases, the exo-amino 
groups of the phosphoramidites are protected with acetyl (for dC), phenoxyacetyl (for dA), 
and isopropyl phenoxyacetyl (for dG). These more labile groups can be removed with 
concentrated ammonium hydroxide solution at room temperature in 2 hours or with 0.05M 
potassium carbonate in methanol at room temperature for 4 hours. However, these 
3 
deprotection and cleavage conditions are not suitable for ODNs containing nucleophile-
labile moieties.  
Scheme 1.1. Solid Phase ODN Synthesis 
1.4 Limitations of Solid Phase ODN Synthesis 
For most purposes, ODNs are synthesized solely using automated solid-phase 
methods. While there have been many advances in the protocols, the widely used method 
still has drawbacks. For instance, the detritylation step uses the abovementioned solution 
of dichloroacetic acid in dichloromethane. These acidic conditions make it impossible to 
incorporate acid-sensitive substrates on ODNs. Furthermore, the use of basic and 
nucleophilic conditions for cleavage and deprotection purposes prevent the practical 
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incorporation of electrophiles such as activated esters, aziridines, epoxides, α-halo 
substituted carbonyl functional groups, as well as alkyl halides. Therefore, there is a need 
for a new technology to overcome these challenges. 
1.5 The Need for Modified ODNs 
ODNs containing electrophilic functionalities are predicted to have wide applications 
in fields such as covalent cross-linking studies with messenger ribonucleic acid (mRNA) 
[5] and protein interactions. [6] Moreover, electrophiles anchored on DNA can enable the 
synthesis of model compounds which can aid in DNA damage findings such as methylation 
and demethylation studies. [7] Over the past several years, topics regarding the uptake, 
metabolism, as well as cellular trafficking of DNA has been noticeably studied. 
Particularly, there has been emerging interest in the hybridization of antisense 
oligonucleotides to mRNAs. The incorporation of electrophilic moieties on ODNs can 
successfully enable the formation of a covalent bond between the modified ODN and the 
target specific mRNA sequence. However, such DNA-based therapeutics are limited to the 
integration of the host genome’s plasmids. Additionally, there is currently no known 
commercially viable cross-linking agents available. [8] Thus, there is a strong necessity for 
nucleophile-labile ODNs. 
1.6 Current Methods to Modify ODNs and Their Drawbacks 
Currently, there are a small number of approaches mentioned in the literature. The first 
type attempts the functionalization of electrophilic moieties on ODN after cleavage and 
deprotection. [8] However, since functionalities are limited in organic chemistry this needs 
5 
to be developed on a case-by-case basis and is therefore restrictive. The idea to use 
protecting groups and linkers that can be cleaved under nearly neutral conditions have been 
mentioned in the literature. In such cases, palladium-removable allyl groups along with 
photo-labile linkers have been used. [9] However, transition metals such as palladium are 
expensive and difficult to remove. Furthermore, it is known that UV irradiation has the 
potential to damage DNA. There have also been attempts to use enzymatic reactions to 
access electrophilic ODNs. [10] This strategy has narrow applicable viability and is 
associated with high costs. 
1.7 Our Non-Nucleophilic Technology to Incorporate 
Electrophiles on ODN 
To overcome the aforementioned problems, we have developed a non-nucleophilic 
technology to install electrophiles on DNA strands. The following paragraphs briefly 
depict the concepts behind the original technology and its improved derivatives.  
6 
1.7.1 Dmoc Technology 
Figure 1.1. Dmoc Phosphoramidites and Dmoc Linker 
We have successfully developed a new technology that allows us to incorporate 
sensitive functionalities on ODNs. As shown in Figure 1.1, the technology is based on the 
design of 1,3-dithiane-2-yl-methoxycarbonyl (Dmoc) protecting groups (1.1-1.3) and 
linkers (1.4) used for ODN synthesis. The Dmoc based groups are stable under all standard 
ODN synthesis conditions. Once the desired ODN length is obtained, the cyanoethyl 
groups on the phosphate backbone are removed with DBU in acetonitrile at room 
temperature in 15 minutes. After inducing the beta elimination, the hydrophilic ODN 
backbone is revealed which can then be subjected to aqueous oxidative conditions to 
oxidize the sulfur moieties into their respective sulfoxide and sulfone states. Once 
7 
oxidation is completed, the Dmoc protecting groups and linker are cleaved under mild 
nearly non-nucleophilic conditions due to the drastically increased acidity of H-2 in the 
1,3-dithiane moieties. Thus, this technology enabled us to incorporate electrophiles on 
ODNs. Specifics are mentioned in the respective chapter section.  
1.7.2 Dmoc Dim Technology 
 
 
 
 
 
 
 
 
Figure 1.2. Dmoc Dim Phosphoramidites 
Since DBU is used to remove the cyanoethyl groups, some base-labile ODNs may 
not be compatible with our technology. Therefore, the Dmoc based protecting groups 
and linker were then further studied to eliminate the need for DBU in acetonitrile and, 
thus, improved the technology. As shown in Figure 1.2, we were able to replace the 
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cyanoethyl group with a 1,3-dithian-2-yl-methyl (Dim) moiety to mask the P(III) of the 
phosphoramidites (1.5-1.8). Therefore, this eliminated the need for DBU and reduced 
the post ODN work up to ultimately two steps – Oxidation of the 1,3-dithiane moieties 
followed by elimination. Utilizing the CPG Dmoc linker 1.4 along with the Dim 
modifications enabled us to incorporate additional electrophiles on ODNs. While 
satisfactory results were obtained using the Dmoc and Dim technology, we still 
experienced one major drawback – The induced oxidized elimination by-product was 
undergoing a 1,4-Michael Addition reaction with the free exo-amino groups on the 
DNA strands, as shown in Scheme 1.2.  
 
 
 
 
 
 
 
Scheme 1.2. Michael Addition of ODN with Dim Elimination By-Product 
Therefore, we needed to use aniline as both the base and a scavenger, as shown in Scheme 
1.3. Specifics are mentioned in the respective chapter section. 
9 
Scheme 1.3. Using Aniline as a Scavenger during ODN Work-Up 
1.7.3 dM-Dmoc Technology 
Figure 1.3. dM-Dmoc Phosphoramidite 
 Since aniline is a potential nucleophile, some ODNs containing nucleophile-labile 
functionalities may not be compatible with the abovementioned technology. Thus, we 
diverted our attention to modifying the exo-amino protecting groups to a more robust 
version. This modified technology uses a dimethyl Dmoc (dM-Dmoc) protecting group for 
10 
the phosphoramidites 1.10-1.12 (Figure 1.3). Indeed, experimental results showed that the 
dimethyl dim elimination by-product is too sterically hindered for the troublesome 1,4-
Michael Addition reaction to occur (Scheme 1.7). Thus, the usage of scavengers (such as 
aniline) were avoided and beta elimination was achieved by aqueous potassium carbonate 
solution (pH=8). 
 
 
 
 
 
 
 
Scheme 1.4. Post ODN Synthesis Work-Up Using dM-Dmoc 
However, some drawbacks were experienced via this technology as well – Particularly, 
premature cleavage of the dM-Dmoc protecting group during the ODN synthesis due to 
repetitive treatment of dichloroacetic acid in dichloromethane. This resulted in minor 
branched side sequences which we were able to resolve at the end. Specifics are mentioned 
in the respective chapter section.  
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Abstract 
Oligodeoxynucleotides (ODNs) containing electrophilic groups are useful in many 
studies including antisense drug development and DNA/protein interaction. Due to the use 
of strong nucleophiles for cleavage and deprotection, traditional ODN synthesis methods 
are not suitable for their preparation. To solve this problem, a new ODN synthesis 
technology using the 1,3-dithiane-2-yl-methoxycarbonyl (Dmoc) function as protecting 
groups and linker has been developed. The Dmoc function is stable under all ODN 
synthesis conditions using the phosphoramidite chemistry. Upon oxidation of the sulfides 
in them, because of the drastically increased acidity of H-2, the groups and linker are 
readily cleaved under nearly non-nucleophilic conditions. Five ODNs including one with 
a thioester group and another with an α-chloroamide function were successfully 
synthesized using the strategy. It is predicted that the technique could be adaptable for the 
synthesis of ODNs containing other electrophiles. 
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2.1 Introduction 
In traditional solid-phase oligodeoxynucleotide (ODN) synthesis, the amino groups 
on the nucleobases are protected with acyl groups that have to be removed with strongly 
nucleophilic reagents such as ammonium hydroxide. The widely used succinyl ester 
linkage is also cleaved under these conditions. For this reason, the methods are not suitable 
for the synthesis of ODN analogues that contain electrophilic functionalities. However, 
such analogues have found or are predicted to have wide applications in areas such as 
covalent cross-linking with messenger ribonucleic acid (mRNA) for antisense drug 
development,1 analysis of nucleic acid and protein interactions by detecting cross-linked 
fragments using mass spectrometry,2 and the synthesis of model compounds of sensitive 
nucleic acid intermediates in cells for deoxyribonucleic acid (DNA) damage and DNA 
methylation and demethylation studies.3 Current strategies for electrophilic ODN synthesis 
include two types. One type uses protecting groups and linkers cleavable under less basic 
or nearly neutral conditions. However, functions in organic chemistry suitable for the need 
are limited. Those used in the literature include the more base-labile phenoxyacetyl based 
groups and linker,4 the palladium-removable allyl groups,3b,5 and the photolabile o-
nitrobenzyl linker.3b,6 ODN synthesis methods using these functionalities for protecting 
and linking still have serious drawbacks. For example, the phenoxyacetyl groups and 
linkers are usually cleaved with dilute K2CO3 in methanol or aqueous ammonium 
hydroxide.4 These conditions are still strongly nucleophilic. Palladium is expensive and 
difficult to remove. UV irradiation can damage ODN. The second type uses traditional 
methods to make an ODN precursor, which is stable under nucleophilic conditions. After 
cleavage and deprotection, the electrophilic functionality is attached to or uncovered from 
16 
the precursor.1c−e, g−j These methods are inconvenient, have to be developed case by case, 
and are not always feasible. Besides the above two strategies, enzymatic reactions have 
also been used to access electrophilic ODNs.1a Drawbacks include narrow applications and 
high cost. Efforts were also made to search for conditions for ODN synthesis without 
nucleobase protection.7 An ideal linker cleavable under non-nucleophilic conditions 
remains to be developed, and the challenge of achieving complete O-phosphitylation over 
N-phosphitylation in the coupling step may be nontrivial. In this paper, we report our 
studies on use of the 1,3-dithian-2-ylmethoxycarbonyl (Dmoc) based protecting group and 
linker for ODN synthesis. Previously, this and the similar 2-(phenylthio)ethyl group had 
been studied for peptide synthesis and thymidine protection, but they have not been tested 
for ODN synthesis.8 We predicted that the Dmoc function would be stable under all ODN 
synthesis conditions. However, upon oxidation of the sulfides to sulfoxides or sulfones 
after synthesis, due to the drastically increased acidity of H-2, they could be cleaved under 
non-nucleophilic conditions. Using that technology, we successfully synthesized five 
ODNs including one containing a thioester and another containing an α-chloroacetyl 
function. The cleavage and deprotection were achieved in three steps under non-
nucleophilic conditions. These electrophilic groups would not survive the nucleophilic 
conditions such as NH4OH and K2CO3/MeOH, while incorporating them into ODNs is 
desirable due to their potential applications such as antisense drug development, sequence-
specific DNA alkylation, and DNA−protein interaction studies.1g,5a,9 We expect that the 
new method would be suitable for the synthesis of other electrophilic ODNs as well and, 
therefore, have a high impact in several research areas. 
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2.2 Results and Discussion 
To carry out an electrophilic ODN synthesis using the Dmoc function for protecting 
and linking, a Dmoc linker such as that in dT-Dmoc-CPG (controlled pore glass) 2.1 and 
the phosphoramidite monomers Dmoc-dC-amidite 2.2, Dmoc-dA-amidite 2.3, and Dmoc-
dG-amidite 2.4 are required (Figure 2.1).  
 
 
 
 
 
 
Figure 2.1. CPG with dT-Dmoc linker and Dmoc amidites 
The corresponding dT monomer is not required because thymidine does not have an amino 
group, and a commercial dT amidite (2.5) can be used. The preparation of CPG 2.1 is 
shown in Scheme 2.1. The anion generated by treating 1,3-dithiane with tBuLi was reacted 
with aldehyde 2.6 to give 2.7. Compound 2.7 was converted to 2.8 by reacting it with 1,1′-
carbonyldiimidazole in the presence of calcium hydride. Reaction of 2.9 with 5′-DMTr-dT 
using DBU as the base gave 2.10. Removal of the TBS group in 2.10 with TBAF afforded 
2.11 (not shown in Scheme 2.1). Attaching 2.11 to CPG to give 2.1 was achieved by 
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reacting 2.11 with succinic anhydride followed by incubation with amino CPG in the 
presence of DCC. Because we installed the 1,3-dithiane moiety at the side of the linkage 
instead of in the linkage, the construction of 2.1 is quite simple.  
 
 
 
 
Scheme 2.1. Synthesis of dT-Dmoc-CPG 
The synthesis of Dmoc amidite 2.2−2.4 is shown in Scheme 2.2. The amino groups of 5′-
DMTr-dC 2.12 and dA 2.13 were conveniently protected using (1,3-dithian-2-yl)methyl 4-
nitrophenylcarbonate (2.14)8c by first protecting the 3′-hydroxyl group with TMSCl 
temporarily followed by stirring the reactants at room temperature with DMAP as the 
catalyst. The products 2.15 and 2.16 were obtained in 100% and 57% yields, respectively. 
Phosphitylation of 2.15 and 2.16 using 2-cyano-N,N,N′,N′-
tetraisopropylphosphorodiamidite (2.17) gave the amidite monomers Dmoc-dC-amidite 
2.2 and Dmoc-dA-amidite 2.3, respectively, in excellent yields. However, when the same 
acylation method was used to synthesize Dmoc-dG, no desired product could be isolated 
probably due to the lower basicity of the amino group of dG.10 We tried several other 
conditions and finally settled with the following procedure. The O-protected dG 2.1811 was 
treated with excess tBuMgCl and 2.14 to give 2.19 in 44% yield. The silyl protecting group 
19 
was then removed by HF−pyridine,12 and without purification the product was reacted with 
DMTr-Cl to give 2.20 (not shown in Scheme 2.2) in 80% yield after flash chromatography. 
Compound 2.20 was phosphitylated using 2.17 to give Dmoc-dG-amidite 2.4 in 77% yield. 
With dT-Dmoc-CPG 2.1 and amidite monomers 2.2−2.4 in hand, before synthesizing 
electrophilic ODNs, we tested the technology by synthesizing three unmodified ODNs. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.2. Synthesis of Amidite Monomers 
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They were 20-mers 5′ HO-TCA TTG CTG CTT ATA CCT CT-OH 3′ (2.20), 5′ HO-TCA 
TTG CTG CTT AGA CCG CT-OH 3′ (2.21), and 5′ HO-TTA GTA GGA CCT ACA CCT 
GT-OH 3′ (2.22). The conditions were the same as those in traditional ODN synthesis using 
the phosphoramidite chemistry. Concentration of the amidites was 0.1M. At the end of 
synthesis, the DMTr group was removed. According to the trityl assay, the coupling yields 
were not negatively affected by the Dmoc linker and protecting groups. For deprotection 
and cleavage, the 2-cyanoethyl groups were first removed by treating with DBU briefly 
(Scheme 2.3). The sulfides in Dmoc were then oxidized with NaIO4 at pH 2 in 3 h.
13 The 
acidity of H-2 in Dmoc is now drastically increased. However, due to the acidic conditions, 
β-elimination did not occur at this stage as indicated by HPLC analysis of the supernatant. 
After removal of the supernatant, residue NaIO4 was washed away with water at pH 2. 
Final cleavage and deprotection of ODN were then induced with an aniline solution at pH 
8 (Scheme 2.3).  
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Scheme 2.3. ODN Deprotection and Cleavage 
The crude ODNs 2.20−2.22 were purified with RP HPLC. The profiles of crude and 
purified 2.20 are shown in Figure 2.2. Those of 2.21−2.22 are shown in the Supporting 
Information. All of the ODNs were analyzed with MALDI-TOF MS, which gave correct 
molecular masses (Supporting Information). We next decided to incorporate the 
nucleophile-sensitive thioester and α-chloroacetyl functions into ODNs. The thioester 
function was used as a phosphate masking group in ODN prodrugs. For the application, 
the thioester had to be kept intact during ODN synthesis, cleavage, and deprotection.5a,9 
ODNs containing an α-chloroacetyl function could find applications in sequence-specific 
alkylation and cleavage of DNA and other areas.1g−j We chose to incorporate the 
electrophilic groups into the middle of the sequences because it is more challenging than 
22 
attaching it to the 5′-end. The required amidites 2.23 and 2.24, which contained the 
thioester and α-chloroacetyl, respectively, were prepared according to Scheme 2.2. 
Compound 2.2514 was coupled with 5-(acetylthio)pentanoic acid (2.26)15 to give 2.27, 
which was phosphitylated to give amidite 2.23. Amidite 2.24 was also prepared from 2.25. 
Acylation of 2.25 with α-chloroacetyl chloride gave 2.28, which was phosphitylated to give 
2.22. Using the Dmoc-CPG 2.1 and amidites 2.2−2.4, we successfully incorporated 2.23 
and 2.24 into ODNs 5′ HO-TCA TTG CTG CTT A-X-A CCT CT−OH3′ (2.30) and 5′ HO-
TCA TTG CTG CTT A-Y-A CCT CT−OH 3′ (2.31), where X and Y are the thioester and 
α-chloroacetyl units introduced with 2.23 and 2.24, respectively. The sequences were 
derived from 2.20 by replacing a T with X or Y. The conditions for ODN synthesis and 
cleavage and deprotection were the same as described above.  
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Figure 2.2. RP HPLC profiles of ODN 2.20 and 2.29 
No modification of the procedure was needed except that a simpler precipitation method 
instead of size-exclusion chromatography was used to separate ODN from small molecules 
after ODN cleavage and deprotection. The ODNs were purified with RP HPLC. MALDI-
TOF MS analyses gave correct molecular masses (Supporting Information). The RP HPLC 
profiles of crude and purified 2.29 are in Figure 2.2. Those of 2.29 are shown in the 
Supporting Information. According to trityl assays, the coupling yields using the Dmoc 
amidites were excellent. To have a direct comparison of these amidites with commercial 
ones, we synthesized ODN 2.20 two times under identical conditions except that, in one 
time, 2.1−2.4 and commercial dT amidite were used and, in another, 2.1 and commercial 
dA, dC, dG and dT amidites were used (Supporting Information). In both syntheses, the 
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CPG 2.1 were used and were from the same batch with identical amounts. A portion of 
both ODNs on the same weight of CPG were cleaved and deprotected with concentrated 
NH4OH under identical conditions (the Dmoc group and linker can also be cleaved with 
NH4OH). RP HPLC analysis gave similar peak areas of full-length ODN. The OD260 values 
of purified ODNs were also very close. These experiments further confirmed that the Dmoc 
protecting groups did not have a negative effect on ODN synthesis efficiency. Cleavage 
and deprotection of the ODN synthesized with Dmoc amidites were also carried out under 
the oxidative conditions using the same amount of CPG as the above two experiments. 
However, the yield of ODN obtained was lower. Both HPLC peak area and OD260 values 
were about one-fourth of those for the experiments involving NH4OH cleavage and 
deprotection. The lower yield may be caused by the loss of ODN during removing aniline 
with Amicon centrifugal filter units. The three-step procedure and the order of the steps for 
cleavage and deprotection used in new technology are important. The removal of the 2-
cyanoethyl groups increases the hydrophilicity of ODNs, which is beneficial for oxidation 
in water in the next step. Performing oxidation under acidic conditions retains ODN on 
CPG, which allows easy removal of NaIO4. The acidic conditions in the oxidation step did 
not cause any noticeable depurination because treating unmodified ODNs from the 
technology with concentrated NH4OH did not give peaks of shorter ODNs in HPLC 
profiles. The excess aniline introduced in the last step is easy to remove due to its small 
size and high solubility in organic solvents. We achieved this by passing it through a size-
exclusion column. We also tested a precipitation method involving adding nBuOH to 
aqueous ODN solutions. ODN was precipitated, and aniline remained in the supernatant, 
which was removed with a pipette.16 Finally, ultrafiltration using an Amicon centrifugal 
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filter unit also proved effective. The Dmoc-based linker and protecting groups are well 
suited for electrophilic ODN synthesis. Before oxidation, H-2 in the function is not acidic 
in normal terms of organic chemistry (pKa∼ 31), which enables Dmoc to be stable during 
ODN synthesis. After oxidation, the pKa of H-2 is lowered to ∼12. Compared to the Fmoc 
protecting group, in which case the pKa of H-9 is ∼22 and the group can be removed by 
the weak base piperidine (pKa of conjugate acid ∼11), the Dmoc linker and protecting 
group were predicted to be readily cleavable under nearly neutral and non-nucleophilic 
conditions. Our results have shown that this is indeed the case. Compared to the ODN 
synthesis methods that used the allyl and o-nitrobenzyl functionalities, the Dmoc method 
does not require any expensive and difficult-to-remove transition metal and DNA-
damageable UV light for deprotection and cleavage. Instead, the readily available and 
easily removable NaIO4 and aniline can accomplish the task. We have successfully shown 
that the technology is suitable for the synthesis of ODNs containing thioester and α-
chloroacetyl amide, which we confirmed to be incompatible with the widely known mild 
deprotection conditions using K2CO3 in MeOH (Supporting Information). Besides these 
two electrophilic groups, other groups such as aldehydes,13 esters, activated esters, 
aziridines,1g epoxides, alkyl halides, vinyl purines,17 methides,18 and maleimides could be 
incorporated into ODNs as well. 
2.3 Conclusion 
In conclusion, we have developed a new ODN synthesis method using the Dmoc 
function as the linker and protecting group. Using the method, deprotection and cleavage 
are carried out in three steps under non-nucleophilic conditions, and therefore, it is useful 
26 
for the synthesis of electrophilic ODNs. Five sequences were successfully synthesized 
using the strategy. One of them contained a nucleophile-sensitive thioester, and another 
contained a sensitive α-chloroacetyl. The coupling yields wereexcellent. The products were 
purified with RP HPLC. MALDI-TOF MS analysis indicated that the ODNs had the 
correctstructure. We expect that the new technology will find applications in various 
research fields that need electrophilic ODNs. 
2.4 Experimental Section 
All reactions were performed in oven-dried glassware under a nitrogen atmosphere 
using standard Schlenk techniques. Reagents and solvents available from commercial 
sources were used as received unless otherwise noted. CH2Cl2, pyridine, and toluene were 
distilled over CaH2. THF was distilled over Na/benzophenone. Thin layer chromatography 
(TLC) was performed using Sigma-Aldrich TLC plates, silica gel 60F-254 over glass 
support, 0.25 μm thickness. Flash column chromatography was performed using Selecto 
Scientific silica gel, particle size 32-63 μm. 1H, 13C and 31P NMR spectra were measured 
on Varian UNITY INOVA spectrometer at 400, 100 and 162 MHz, respectively; chemical 
shifts (δ) were reported in reference to solvent peaks (residue CHCl3 at δ 7.24 ppm for 1H 
and CDCl3 at δ 77.00 ppm for 13C, and H3PO4 at δ 0.00 ppm for 31P). ODNs were 
synthesized on ABI 394 (2.20-2.22) and MerMade 6 (2.29-2.30) solid phase synthesizers. 
RP HPLC was performed on a JASCO LC-2000Plus System: pump, PU-2089Plus 
Quaternary Gradient; detector UV-2075Plus. A C-18 reverse phase analytical column (5 
μm diameter, 100 Å, 250 × 3.20 mm) was used. Solvent A: 0.1 M triethylammonium 
acetate, 5% acetonitrile. Solvent B: 90% acetonitrile. All profiles were generated by 
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detection of absorbance of ODN at 260 nm using the linear gradient solvent system: solvent 
B (0%-45%) in solvent A over 60 min followed by solvent B (45%-100%) in solvent A 
over 20 min at a flow rate of 0.5 mL/min. Lcaa-CPG (pore size 497 Å) was a gift from 
Prime Synthesis, Inc. D-SaltTM dextran desalting column (5K MWCO, 10 mL) was 
purchased from Pierce Biotechnology, Inc. Polyacrylamide desalting column (5K MWCO, 
10 mL) was from Thermo Scientific. Amicon® centrifugal filter units (3K NMWL) were 
purchased from Sigma-Aldrich.  
Compound 2.7 
To a solution of 1,3-dithiane (3.25 g, 27.1 mmol) in dry THF (50 mL) was added 
tBuLi (1.7 M in pentane, 16.0 mL, 27.1 mmol) dropwise at -78 °C. The mixture was stirred 
under nitrogen while warming to -40 °C gradually. After stirring at this temperature for 1 
h, it was cooled to -78 °C, and a solution of 2.6 (4.88 g, 22.6 mmol) in dry THF (30 mL) 
was added slowly via cannula. Stirring was continued at -78 °C for 15 min, and the reaction 
was then quenched with sat. NH4Cl (50 mL). The organic layer was separated and the 
aqueous layer was extracted with EtOAc (50 mL × 3). The combined organic layer was 
washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated. 
Flash column chromatography (SiO2, 9:1 hexanes/EtOAc) gave 2.8 as a colorless oil (5.40 
g, 71%): Rf = 0.2 (9:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 0.02 (s, 6H, H-1), 
0.86 (s, 9H, H-2), 1.38-1.48 (m, 1H, H-3), 1.49-1.59 (m, 4H, H-3), 1.77-1.84 (m, 1H, H-
3), 1.89-1.98 (m, 1H, H-4), 2.01-2.10 (m, 1H, H-4), 2.43 (d, J = 3.6 Hz, 1H, H-5), 2.68-
2.78 (m, 2H, H-6), 2.86-2.94 (m, 2H, H-6), 3.59 (t, J = 10.4 Hz, 2H, H-7), 3.80-3.85 (m, 
1H, H-8), 3.88 (d, J = 6 Hz, 1H, OH); 13C NMR (100 MHz, CDCl3) δ -5.3, 18.3, 22.1, 25.7, 
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26.0, 28.0, 28.5, 32.6, 33.8, 52.5, 63.0, 72.2; HRMS (ESI) m/z calcd for C15H32O2S2SiH 
[M+H]+ 337.1691, found 337.1695. 
Compound 2.8 
Carbonyldiimidazole (2.61 g, 16.1 mmol), 2.7 (2.16 g, 6.4 mmol), CaH2 (90% 
grade, 0.75 g, 16.1 mmol) and dry toluene (100 mL) were combined and stirred at rt for 8 
h. The mixture was filtered, and the filtrate was concentrated. Flash column 
chromatography (SiO2, 3:1 hexanes/EtOAc) gave 2.8 as a thick oil (2.83 g, 100%): Rf = 
0.2 (3:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 0.01 (s, 6H, H-1), 0.82 (s, 9H, H-
2), 1.39-1.56 (m, 4H, H-3), 1.80-2.08 (m, 4H, H-3 and H-4), 2.67-2.78 (m, 2H, H-5), 2.84-
2.95 (m, 2H, H-5), 3.57 (t, J = 4 Hz, 2H, H-6), 4.10 (d, J = 4 Hz, 1H, H-7), 5.28-5.33 (m, 
1H, H-8), 7.04 (s, 1H, H-9), 7.40 (s, 1H, H-10), 8.12 (s, 1H, H-11); 13C NMR (100 MHz, 
CDCl3) δ -5.4, 18.2 21.7, 25.4, 25.8, 28.4, 28.6, 31.4, 32.2, 48.9, 62.4, 78.4, 117.2, 130.6, 
137.2, 148.3; HRMS (ESI) m/z calcd for C19H34N2O3S2SiH [M+H]
+ 431.1858, found 
431.1858. 
Compound 2.9:  
5′-DMTr-thymidine (3.72 g, 6.8 mmol), 2.8 (1.96 g, 4.6 mmol) and DBU (0.21 g, 
0.20 mL, 1.4 mmol) and toluene (50 mL) were combined and stirred at rt. After 8 h, the 
mixture was concentrated and purified with flash column chromatography (SiO2, 3:1 
hexanes/EtOAc with 0.5% Et3N). Compound 2.9 was obtained as a white foam (3.14 g, 
76%): m.p. 81.2-82.6 °C; Rf = 0.45 (1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 
0.00 (s, 6H, H-1), 0.84 (s, 9H, H-2), 1.31 (s, 3H, H-3), 1.36-2.00 (m, 8H, H-4), 2.34-2.74 
(m, 4H, H- 4), 2.80-2.89 (m, 2H, H-4), 3.41-3.47 (m, 2H, H-5), 3.57 (t, J = 8 Hz, 2H, H-
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6), 3.75 (s, 6H, H-7), 3.94 (d, J = 8 Hz, 1H, H-8), 4.20 (s, 1H, H-9), 4.91-4.96 (m, 1H, H-
10), 5.35 (d, J = 8 Hz, 1H, H- 10), 6.43 (dd, J = 4 Hz, 8 Hz, 1H, H-11), 6.79 (d, J = 8 Hz, 
4H, H-12), 7.18-7.31 (m, 8H, H-13), 7.31-7.33 (m, 1H, H-14), 7.54 (s, 1H, H-15), 8.08 (br 
s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ -5.3, 11.6, 18.3, 21.7, 25.4, 26.0, 28.4, 28.6, 
31.6, 32.3, 37.9, 48.9, 55.3, 62.7, 63.7, 78.8, 78.9, 84.0, 84.3, 87.2, 111.5, 113.3, 127.2, 
128.0, 128.1, 130.1, 135.2, 135.3, 135.4, 144.2, 150.0, 154.3, 158.8, 163.3; HRMS (ESI) 
m/z calcd for C47H62N2O10S2SiNa [M+Na]
+ 929.3513, found 929.3497. 
Compound 2.10:  
 
To a solution of 2.9 (1.47 g, 1.6 mmol) in THF (40 mL) at 0 °C was added TBAF (1.95 
mL, 1.0 M in THF, 1.9 mmol) dropwise. The mixture was stirred for 8 h while warming to rt. The 
contents were poured into a separation funnel and partitioned between EtOAc (40 mL) and H2O 
(40 mL). The aqueous layer was extracted with EtOAc (30 mL × 2). The combined organic layer 
was dried over anhydrous Na2SO4, filtered and concentrated. Flash column chromatography (SiO2, 
1:1 hexanes/EtOAc) gave 2.10 as a white foam (0.96 g, 75%): m.p. 90.6- 92.3 °C; Rf = 0.3 (1:3 
hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.35 (s, 3H, H-1), 1.41- 1.63 (m, 4H, H-2), 1.69-
1.81 (m, 2H, H-2), 1.89-2.08 (m, 2H, H-2), 2.37-2.44 (m, 1H, H-2), 2.56- 2.75 (m, 3H, H-2), 2.84-
2.93 (m, 2H, H-2), 3.42-3.51 (m, 2H, H-3), 3.61-3.65 (m, 2H, H-4), 3.77 (s, 6H, H-5), 3.98 (d, J = 
8 Hz, 1H, H-6), 4.24 (s, 1H, H- 7), 4.97-5.01 (m, 1H, H-8), 5.34 (d, J = 4 Hz, 1H, H-8), 6.42 (t, J 
= 4 Hz, 8 Hz, H-9), 6.82 (d, J = 8 Hz, 4H, H-10), 7.20-7.34 (m, 8H, H-11), 7.34-7.37 (m, 1H, H-
12), 7.58 (s, 1H, H-13), 8.78 (s, 1H, NH); 13C NMR (100 MHz, CDCl3) δ 11.6, 14.2, 21.0, 21.6, 
25.4, 28.4, 28.6, 31.6, 32.1, 38.0, 48.9, 55.2, 60.4, 62.4, 63.7, 78.7, 79.1, 83.7, 84.4, 87.2, 111.6, 
113.3, 127.2, 128.0, 128.1, 130.1, 130.1, 135.1, 135.2, 135.3, 144.2, 150.3, 154.2, 158.8, 158.8, 
163.5; HRMS (ESI) m/z calcd for C41H48N2NaO10S2 [M+Na]+ 815.2648, found 815.2636. 
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dT-Dmoc-CPG 2.1:  
A mixture of 2.10 (0.10 g, 0.13 mmol), succinic anhydride (0.05 g, 0.50 mmol), 
and DMAP (0.03 g, 0.25 mmol) in anhydrous pyridine (3 mL) was stirred at rt. After 2 
days, the contents were partitioned between EtOAc (5 mL) and H2O (5 mL). The organic 
layer was washed with sat. NaHCO3 and brine, dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was dissolved in dry DMF (3 mL) and mixed with amino-lcaa-
CPG (0.251 g, 0.027 mmol, 107 μmol/g, 497 Å, Prime Synthesis, Inc.) and DCC (0.027 
mL, 1.0 M in CH2Cl2, 0.027 mmol). After standing at rt for 2 days, the supernatant was 
removed, and the CPG was washed with pyridine (3 mL × 5). To the CPG was added a 
capping solution (0.1 M DMAP in pyridine/Ac2O, 9:1, v/v; 5 mL), and the mixture was 
allowed to stand at rt for 2 days. The supernatant was removed, and the CPG was washed 
with pyridine (3 mL × 5), MeOH (3 mL × 3), DMF (3 mL × 3) and acetone (3 mL × 5), 
and dried under vacuum. 
Compound 2.14:  
A solution of 5′-DMTr-dC (11, 2.60 g, 4.9 mmol) and TMSCl (1.60 g, 1.87 mL, 
14.7 mmol) in pyridine (50 mL) was stirred at rt for 30 min. Compound 13 (3.10 g, 9.8 
mmol) and DMAP (0.30 g, 2.5 mmol) in pyridine (15 mL) were added via cannula, and the 
mixture was stirred for 8 h. After cooling to 0 °C, H2O (10 mL) was added, and the mixture 
was stirred for 5 min. Concentrated NH4OH (15 mL) was then added, and the mixture was 
stirred at 0 °C for an additional 30 min. The content was poured into a separation funnel 
containing 5% NaHCO3 (30 mL), and extracted with CH2Cl2 (30 mL × 2). The extracts 
were dried over anhydrous Na2SO4, filtered and concentrated. Flash column 
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chromatography (SiO2, 1:2:5:2:2:1 hexanes/EtOAc/ Et2O/MeCN/MeOH/Et3N) gave 2.15 
as a white foam (4.02 g, 100%): m.p. 121.1- 123.4 °C; Rf = 0.32 (1:2:5:2:2:1 
hexanes/EtOAc/Et2O/MeCN/MeOH /Et3N); 
1H NMR (400 MHz, CDCl3) δ 1.93-2.09 (m, 
2H, H-1), 2.21-2.27 (m, 1H, H-1), 2.41 (br s, 1H, OH), 2.62-2.96 (m, 5H, H-1), 3.37-3.41 
(m, 2H, H-2), 3.79 (s, 6H, H-3), 4.09 (t, J = 6 Hz, 1H, H-4), 4.46-4.48 (m, 4H, H- 5), 6.23 
(t, J = 6 Hz, 1H, H-6), 6.83 (d, J = 8 Hz, 4H, H-7), 6.96 (d, J = 8 Hz, 1H, H-8), 7.20-7.39 
(m, 9H, H-9), 8.23 (d, J = 8 Hz, 1H, H-10); 13C NMR (100 MHz, CDCl3) δ 15.4, 27.3, 
41.9, 42.8, 55.2, 62.6, 65.6, 70.7, 86.3, 86.9, 113.2, 127.0, 128.0, 128.1, 130.0, 135.3, 
135.4, 135.4, 144.2, 158.6, 162.1; HRMS (ESI) m/z calcd for C36H39N3O8S2H [M+H]
+ 
706.2251, found 706.2249. 
Dmoc-dC-amidite 2.2:  
A round-bottom flask containing 2.15 (0.69 g, 1.0 mmol) and a magnetic stirring 
bar was evacuated and then refilled with nitrogen. The evacuation and nitrogen-filling 
cycle was repeated for two more times. Dry CH2Cl2 (10 mL), 2- cyanoethyl-N,N,N′,N′-
tetraisopropylphosphoramidite (2.17, 0.33 g, 0.34 mL, 1.09 mmol), and a solution of 1H-
tetrazole in CH3CN (0.45 M, 2.41 mL, 1.09 mmol) were added via syringes sequentially. 
After stirring at rt for 2 h, the mixture was concentrated to dryness by a nitrogen flow over 
its surface. The residue was purified with flash column chromatography (SiO2, 1:1 
hexanes/EtOAc) giving 2.2 as a white foam (800 mg, 89%): Rf = 0.32 (1:3 
hexanes/EtOAc); 1H NMR (400 MHz CDCl3) δ 1.14 (d, J = 6 Hz, 12H, H- 1), 1.90-2.07 
(m, 1H, H-2), 2.24-2.30 (m, 1H, H-2), 2.41 (t, J = 8 Hz, 2H, H-3), 2.64-2.71 (m, 4H, H-2), 
2.88-2.93 (m, 2H, H-2), 3.35-3.57 (m, 6H, H-4), 3.77 (s, 6H, H-5), 4.17-4.18 (m, 1H, H-
32 
6), 4.45-4.64 (m, 4H, H-7), 6.22 (t, J = 6 Hz, 1H, H-8), 6.81-6.88 (m, 5H, H-9, H-10), 7.22-
7.38 (m, 9H, H-11), 8.27 (d, J = 8 Hz, 1H, H-12); 13C NMR (100 MHz, CDCl3) δ 20.1, 
24.6, 27.2, 29.9, 40.8, 42.7, 43.3, 55.2, 58.1, 58.3, 61.9, 65.6, 71.6, 85.6, 86.8, 94.5, 113.2, 
117.3, 127.0, 127.9, 128.2, 129.6, 130.0, 130.1, 135.2, 135.3, 144.0, 144.3, 158.6, 162.0; 
31P NMR (162 MHz, CDCl3) δ 150.4; HRMS (ESI) m/z calcd for C45H56N5O9PS2H 
[M+H]+ 906.3336, found 906.3342. 
Compound 2.15:  
The procedure for 2.14 was used: White foam; yield 57%; m.p. 108.2-111.4 °C; Rf 
= 0.47 (1:2:5:2:2:1 hexanes/EtOAc/Et2O/MeCN /MeOH/Et3N); 
1H NMR (400 MHz, 
CDCl3) δ 1.89- 2.04 (m, 2H, H-1), 2.50-2.97 (m, 6H, H-1), 3.37 (d, J = 4 Hz, 2H, H-2), 
3.72 (s, 6H, H-3), 4.09-4.16 (m, 1H, H-4), 4.16-4.19 (m, 1H, H-5), 4.52 (d, J = 4 Hz, 2H, 
H-5), 4.68-4.71 (m, 1H, H-5), 6.46 (t, J = 6 Hz, 1H, H-6), 6.73-6.75 (d, J = 8 Hz, 4H, H-
7), 7.12- 7.35 (m, 9H, H-8), 8.13 (s, 1H, H-9), 8.66 (s, 1H, H-10); 13C NMR (100 MHz, 
CDCl3) δ 25.4, 27.3, 40.2, 43.0, 55.2, 65.3, 72.2, 84.6, 86.2, 86.5, 113.1, 122.3, 126.9, 
135.5, 141.4, 149.2, 158.4; HRMS (ESI) m/z calcd for C37H39N5O7S2H [M+H]
+ 730.2364, 
found 730.2366. 
 
Dmoc-dA-amidite 2.3:  
The procedure for 2.1 was used: White foam; yield 88%; Rf = 0.4 (1:1:1 
hexanes/EtOAc/Et3N); 1H NMR (400 MHz, CDCl3) δ 1.17 (d, J = 6 Hz, 12H, H-1), 1.94- 2.07 (m, 
1H, H-2), 2.41 (t, J = 8 Hz, 2H, H-3), 2.52-2.99 (m, 7H, H-2), 3.32-3.41 (m, 2H, H-4), 3.55-3.72 
(m, 4H, H-5), 3.76 (s, 6H, H-6), 4.13 (t, J = 8 Hz, 1H, H-7), 4.28-4.31 (m, 1H, H-8), 4.56 (d, J = 8 
33 
Hz, 2H, H-9), 4.74-4.79 (m, 1H, H-8), 6.45 (t, J = 6 Hz, 1H, H-10), 6.77 (d, J = 8 Hz, 4H, H- 11), 
7.16-7.37 (m, 9H, H-12), 8.16 (s, 1H, H-13), 8.68 (s, 1H, H-14); 13C NMR (100 MHz, CDCl3) δ 
20.4, 20.5, 24.7, 24.8, 25.7, 39.7, 43.2, 43.4, 55.4, 63.5, 65.6, 73.6, 73.8, 85.0, 86.2, 86.3, 86.7, 
113.3, 117.6, 122.7, 127.1, 128.0, 128.4, 130.3, 135.8, 135.8, 141.7, 144.7, 149.5, 150.8, 151.1, 
152.9, 158.7; 31P NMR (162 MHz, CDCl3) δ 150.0; HRMS (ESI) m/z calcd for C46H56N7O8PS2H 
[M+H]+ 930.3448, found 930.3441. 
Compound 2.19:  
To a solution of compound 2.17 (2.56 g, 5.04 mmol) in HMPA (5 mL) and THF 
(50 mL) was added tert-butylmagnesium chloride (1 M in THF, 15.1 mL, 15.1 mmol) 
dropwise at -78 °C. After addition, the mixture was allowed to warm to rt slowly, stirred 
at rt for 30 min, and then cooled to -78 °C again. A solution of 2.13 (3.97 g, 12.6 mmol) in 
THF (25 mL) was added dropwise. After stirring at rt for 8 h, the reaction was quenched 
with MeOH (8 mL). Volatiles were evaporated under reduced pressure. The residue was 
dissolved in EtOAc and washed sequentially with 0.15 M EDTA, saturated NaHCO3, and 
brine. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated. Flash 
chromatography (SiO2, 19:1 CHCl3/MeOH) gave 2.18 (1.53 g, 44 %) as a white solid. To 
the solution of 2.18 (0.57 g, 0.83 mmol) in dry pyridine (10 mL) was added HF-pyridine 
(70%, 357 mg, 12.5 mmol) at 0 °C. After stirring at rt for 2 h, excess fluoride was quenched 
with MeOSiMe3 (1.30 g, 12.5 mmol) by stirring at rt for 8 h. Volatiles were evaporated 
under reduced pressure. The residue was co-evaporated with dry pyridine (5 mL × 3), and 
then dissolved in dry pyridine (20 mL). To the solution, dimethoxytrityl chloride (0.28 g, 
0.83 mmol) was added. After stirring at rt for 8 h, the mixture was partitioned between 
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CH2Cl2 and 5% NaHCO3. The organic layer was dried over anhydrous Na2SO4, filtered 
and concentrated. Flash chromatography (SiO2, 9:1 EtOAc/MeOH) gave 2.19 (1.06 g, 
80%) as a white foam: m.p. 159 – 161 °C; Rf = 0.2 (9:1 EtOAc/MeOH); 1H NMR (400 
MHz, CDCl3) δ 1.94-2.06 (m, 2H, H-1), 2.48- 2.59 (m, 2H, H-1), 2.63-2.96 (m, 4H, H-1), 
3.27-3.41 (m, 2H, H-2), 3.68 (s, 6H, H-3), 4.10 (t, J = 8 Hz, 1H, H-4), 4.15-4.18 (m, 1H, 
H-5), 4.57 (d, J = 8 Hz, 2H, H-6), 4.87-4.91 (m, 1H, H-5), 6.22 (t, J = 6 Hz, 1H, H-7), 6.68 
(dd, J = 9 Hz, 3 Hz, 4H, H-8), 7.07-7.33 (m, 9H, H-9), 7.68 (s, 1H, H- 10); 13C NMR (100 
MHz, CDCl3) δ 10.8, 14.2, 25.4, 27.0, 40.1, 42.6, 45.8, 55.2, 60.4, 64.3, 65.7, 71.7, 84.3, 
86.4, 86.5, 113.0, 120.9, 126.8, 135.7, 144.5, 148.4, 154.4, 155.8, 158.4; HRMS (ESI) m/z 
calcd for C37H39N5O8S2H [M+H]
+ 746.2313, found 746.2311. 
Dmoc-dG-amidite 2.4:  
The procedure for 2.1 was used: White foam; yield 77%; Rf = 0.5 (29:1 
EtOAc/MeOH); 1H NMR (400 MHz, CDCl3) δ 1.12-1.15 (m, 12H, H-1), 1.97-2.03 (m, 
2H), 2.32-2.95 (m, 8H, H-2, H-3), 3.33 (d, J = 4 Hz, 2H, H-4), 3.51-3.63 (m, 4H, H-5), 
3.73 (s, 6H, H-6), 3.96 (t, J = 10 Hz, 1H, H-7), 4.24-4.47 (m, 1H, H-8), 4.50 (d, J = 8 Hz, 
2H, H-9), 4.68- 4.74 (m, 1H, H-8), 6.19 (t, J = 6 Hz, 1H, H-10), 6.73-6.76 (m, 4H, H-11), 
7.13-7.38 (m, 9H, H- 12), 7.74 (s, 1H, H-13); 13C NMR (100 MHz, CDCl3) δ 20.2, 20.3, 
24.5, 24.5, 24.6, 26.8, 39.4, 42.1, 43.2, 43.3, 55.2, 57.8, 58.0, 63.7, 65.6, 73.7, 73.8, 84.6, 
86.0, 86.3, 113.1, 117.3, 121.7, 126.9, 127.8, 128.0, 130.0, 135.7, 137.5, 144.5, 146.2, 
148.0, 153.0, 158.5; 31P NMR (162 MHz, CDCl3) δ 149.4; HRMS (ESI) m/z calcd for 
C46H56N7O9PS2H [M+H]
+ 946.3397, found 946.3405. 
Compound 2.27:  
35 
To a solution of 5- (acetylthio)pentanoic acid (2.26, 100 mg, 0.57 mmol) in dry 
CH2Cl2 (10 mL) at 0 °C was added DCC (0.63 mL, 1.0 M in CH2Cl2, 0.63 mmol) dropwise 
under argon. After stirring at 0 °C for 20 min, compound 2.25 (223 mg, 0.57 mmol) in dry 
CH2Cl2 (10 mL) was added via cannula and the mixture was stirred for 12 h while warm 
to rt gradually. The content was poured into a separatory funnel containing 5% NaHCO3 
(20 mL), and extracted with CH2Cl2 (20 mL × 2). The extracts were dried over anhydrous 
Na2SO4, filtered and concentrated. Flash column chromatography (SiO2, 1:1:0.05 
hexanes/EtOAc/Et3N) gave 27 as a white sticky foam (240 mg, 77%): Rf = 0.35 (1:2 
hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.50-1.69 (m, 4H, H-1), 2.09 (t, J = 7.12 
Hz, 2H, H-2), 2.29 (s, 3H, H-3), 2.82 (t, J = 7.12 Hz, 2H, H-4), 3.09-3.22 (m, 3H, H- 5), 
3.49-3.55 (m, 1H, H-5), 3.76 (s, 6H, H-6), 3.84-3.88 (m, 1H, H-7), 5.85 (br t, J = 7.12 Hz, 
NH), 6.81 (d, J = 6.92 Hz, 4H, H-8), 7.19-7.41 (m, 9H, H-9); 13C NMR (100 MHz, CDCl3) 
δ 24.8, 28.8, 28.9, 30.9, 35.9, 43.2, 55.4, 64.9, 70.5, 86.4, 113.4, 127.1, 128.1, 128.3, 130.2, 
135.9, 144.8, 158.7, 174.0; HRMS (ESI) m/z calcd for C31H37NO6SNa [M+Na]
+ 574.2239, 
found 574.2244. 
Compound 2.23:  
To the solution of 2.27 (100 mg, 0.21 mmol) in CH2Cl2 (2 mL) was added 
diisopropylammonium tetrazolide (54 mg, 0.32 mmol) and 2.16 (97 mg, 0.32 mmol), and 
the reaction mixture was stirred under nitrogen at rt for 2 h. The mixture was loaded onto 
a column (SiO2) and eluted with the solvent mixture EtOAc/hexanes/Et3N (20:20:1). 
Compound 2.23 was obtained as a pale yellow oil (130 mg, 82%): two diastereoisomers, 
Rf = 0.50 (20:20:1 EtOAc/hexanes/Et3N); 1H NMR (400 MHz, CDCl3) δ 1.01-1.31 (m, 
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12H, H-1), 1.45-4.68 (m, 4H, H-2), 2.04 (t, J = 6.7 Hz, 1H, H-3), 2.11 (t, J = 6.7 Hz, 1H, 
H-3), 2.29 (s, 3H, H-4), 2.44 (t, J = 6.3 Hz, 1H, H-5), 2.62 (t, J = 6.2 Hz, 1H, H-5), 2.82 (t, 
J = 7.1 Hz, 1H, H-6), 2.83 (t, J = 7.1 Hz, 1H, H- 6), 3.05-3.10 (m, 0.5H, H-7), 3.15-3.24 
(m, 1H, H- 7), 3.28-3.36 (m, 0.5H, H-7), 3.41-3.69 (m, 4H, H- 7), 3.69-3.80 (m, 1H, H-8), 
3.75 (s, 3H, H-9), 3.76 (s, 3H, H-9), 3.81-3.91 (m, 1H, H-8), 3.95-4.08 (m, 1H, H-10), 5.76 
(t, J = 5.6 Hz, 0.5H, NH), 6.05 (t, J = 5.2 Hz, 0.5H, NH), 6.79 (d, J = 7.6 Hz, 2H, H- 11), 
6.81 (d, J = 5.6 Hz, 2H, H-11), 6.16-7.29 (m, 7H, H-12), 7.41-7.43 (m, 2H, H-12); 31P 
NMR (162 MHz, CDCl3) δ 149.9, 150.3; HRMS (ESI) m/z calcd for C40H54N3O7PSNa 
[M+Na]+ 774.3318, found 774.3316. 
Compound 2.28:  
Triethylamine (0.267 mL, 1.92 mmol) was added to a solution of compound 2.25 
(630 mg, 1.6 mmol) in dry CH2Cl2 (15 mL) and cooled to -10 °C under argon. α-
chloroacetyl chloride was added dropwise over 5 min. The mixture was stirred for 12 h 
while warming to rt slowly. After concentration under reduced pressure, the residue was 
purified with flash column chromatography (SiO2, 1:1:0.05 hexanes/EtOAc/Et3N). 
Compound 2.28 was obtained as a white foam (160 mg, 21%): Rf = 0.30 (1:1 
hexanes/EtOAc). 1H NMR (400 MHz, CDCl3) δ 2.92 (br s, 1H, OH), 3.15-3.23 (m, 2H, H-
1), 3.28- 3.34 (m, 1H, H-1), 3.56-3.62 (m, 1H, H-1), 3.80 (s, 6H, H-2), 3.88-3.94 (m, 1H, 
H-3), 4.00 (s, 2H, H-4), 6.85 (d, J = 8.9 Hz, 4H, H-5), 6.91 (t, J = 5.4 Hz, 1H, NH), 7.20-
7.33 (m, 7H, H-6), 7.43 (dd, J = 11.2, 1.4 Hz, 2H, H-6); 13C NMR (100 MHz, CDCl3) δ 
42.7, 43.1, 55.4, 65.0, 70.0, 86.6, 113.4, 127.2, 128.1, 129.4, 135.9, 144.7, 158.8, 167.0; 
HRMS (ESI) m/z calcd for C26H28ClNO5Na [M+Na]
+ 492.1554, found 492.1558. 
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Compound 2.24:  
The procedure for 2.23 was used: white foam; yield 78%; two diastereoisomers, Rf 
= 0.4 and 0.5 (2:1 EtOAc/hexanes); 1H NMR (400 MHz, CDCl3) δ 1.11-1.24 (m, 12H, H-
1), 2.41 (t, J = 6.5 Hz, 1H, H-2), 2.63 (t, J = 6.3 Hz, 1H, H-2), 3.05-3.09 (m, 0.5H, H-3), 
3.19-3.28 (m, 1H, H-3), 3.33-3.45 (m, 0.5H, H-3), 3.50-3.68 (m, 4H, H-3), 3.50-3.78 (m, 
1H, H-5), 3.76 (s, 3H, H-4), 3.77 (s, 3H, H-4), 3.84-3.94 (m, 1H, H-5), 3.96-4.15 (m, 3H, 
H-6, H-7), 6.70-6.83 (m, 4H, H-8), 7.17-7.48 (m, 9H, H-9); 31P NMR (162 MHz, CDCl3) 
δ 149.90, 149.94; HRMS (ESI) m/z calcd for C35H45ClN3O6PH [M+H]+ 670.2813, found 
670.2809. 
ODN synthesis, deprotection, cleavage and analysis:  
The ODNs were synthesized on ABI 394 (2.20-2.22, 60 mg CPG used) and 
MerMade 6 (2.29-2.30, 24 mg CPG used) synthesizers using dT-Dmoc-CPG 2.1, Dmoc 
amidites 2.2-2.4, amidites 2.23-2.24 and commercial dT amidite. The conditions suggested 
by synthesizer manufactures for 1 μmol synthesis were used in all cases. The average 
stepwise coupling yields for 2.20-2.22 were 98.6, 98.7, and 98.6%, respectively. Those for 
2.29-2.30 were not available as the MerMade synthesizer does not have the reading. After 
synthesis, the CPG was divided into ten (2.20-2.22) or four (2.29-2.30) equal portions. One 
portion was suspended in a solution of DBU in CH3CN (1:9 DBU/CH3CN, v/v, 500 μL), 
and was gently shaken at rt for 15 min. The supernatant was removed with a pipette, and 
the CPG was washed with CH3CN (200 μL × 3). To the CPG, an acidic NaIO4 solution 
(0.1 M in 970 μL H2O and 30 μL AcOH, pH 2) was added. After shaking in dark at rt for 
3 h, the supernatant was transferred into a centrifugal tube. The CPG was washed with 
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dilute acetic acid (3:97 AcOH/H2O, v/v, pH 2, 200 μL × 3). HPLC analysis of the 
supernatant and washes indicated that the ODN was not cleaved from CPG at this time. To 
the CPG was added a solution of aniline (3:97 aniline/H2O, v/v, 1 mL, pH 8), and the 
suspension was shaken at rt for 3 h. The supernatant was transferred into a centrifugal tube. 
The CPG was washed with water (200 μL × 3). For ODNs 2.20-2.22, the combined solution 
was concentrated to ~500 μL (but not to dryness, in some cases, no concentration was 
carried out), loaded onto a dextran or polyacrylamide desalting column (5K MWCO, 10 
mL), and eluted with H2O. Fractions containing ODN were combined and concentrated. 
The ODN was dissolved in 50 μL H2O, and 20 μL was injected into RP HPLC to generate 
the crude ODN trace. The major ODN peak was collected, concentrated, dissolved in 20 
μL water, and injected into HPLC to generate the pure ODN trace. In several trials, we 
used Amicon® centrifugal filter units to remove small molecules. The results were similar. 
For ODNs 2.29-2.30, the supernatant and water washes were combined and concentrated 
to ~50 μL (but not to dryness). To the solution, 500 μL nBuOH was added. The mixture 
was vortexed and centrifuged for 10 min. The supernatant was removed without disturbing 
with a pipette. The residue was dissolved in 50 μL H2O, and 20 μL was injected into RP 
HPLC to generate the crude ODN trace. The major ODN peak was collected, concentrated 
to dryness, dissolved in 20 μL H2O, and injected into HPLC to generate the pure ODN 
trace. All pure ODNs were analyzed with MALDI-TOF MS, and correct molecular masses 
were observed. 
ODN deprotection and cleavage protocol  
 
Standard procedure should be used for ODN synthesis. No modification of conditions is 
required. The deprotection and cleavage of 0.1 μmol crude ODN is used for the description of the 
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protocol.  
1. Place crude ODN on CPG in a 1.5 mL centrifugal tube. Add 500 μL DBU solution in 
CH3CN (1:9 DBU/CH3CN). Shake gently at rt for 15 min.  
2. Spin the tube gently and briefly to bring down CPG (and also the liquids). 
3. Remove the supernatant with a pipette. 
4. Wash the CPG with CH3CN (200 μL × 3). 
5. Add acidic NaIO4 solution (0.1 M in 970 μL H2O and 30 μL AcOH, pH 2). 
6. Wrap the tube with an aluminum foil, and gently shake at rt for 3 h. 
7. Transfer the supernatant to another centrifuge tube. Wash the CPG with dilute acetic acid 
(3:97 AcOH/H2O, v/v, 200 μL × 3. The ODN is still on CPG at this time, but keep the 
supernatant and washes in case that the ODN falls off. If it falls off, size-exclusion 
chromatography and Amicon® ultra filtration are options to separate ODN from NaIO4 
and other small molecules). 
8. Add aniline solution (3:97 aniline/H2O, 1 mL, pH 8) to the CPG, and shake at rt for 3 h. 
9. Transfer the supernatant to another centrifuge tube. Wash the CPG with water (200 μL × 
3). Combine the supernatant and washes. 
10. Concentrate (but do not completely dry) the supernatant and washes to ~50 μL and add 500 
μL nBuOH. Vortex for 30 sec and centrifuge for 10 min. 
11. Carefully remove the supernatant with a pipette. The residue is crude ODN, which can be 
purified with RP HPLC. 
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12. Alternatively, from step 9, load the combined supernatant and washes (concentration is not 
needed unless the volume exceeds 1.5 mL) onto a dextran desalting column (5K MWCO, 
10 mL), and elute with water. Combine the fractions containing ODN. Evaporate volatiles. 
The residue is crude ODN, which can be purified with RP HPLC. 
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Chapter 3 Sensitive ODN Synthesis Using Dim for 
Phosphate Protection 
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Abstract 
In traditional oligodeoxynucleotide (ODN) synthesis, phosphate groups are 
protected with 2-cyanoethyl group, and amino groups are protected with acyl groups. At 
the end of ODN synthesis, deprotection is achieved with strong bases and nucleophiles. 
Therefore, traditional technologies are not suitable for the synthesis of ODNs containing 
sensitive functionalities. To address the problem, we report the use of Dim and Dmoc 
groups, which are based on the 1,3‐dithian‐2‐yl-methyl function, for phosphate and amine 
protection for solid phase ODN synthesis. Using the new Dim-Dmoc protection, 
deprotection was achieved under mild oxidative conditions without using any strong bases 
and nucleophiles. As a result, the new technology is suitable for the synthesis of ODNs 
containing sensitive functions. To demonstrate feasibility, seven 20-mer ODNs including 
four that contain the sensitive ester and alkyl chloride groups were synthesized, purified 
with RP HPLC and characterized with MALDI-TOF MS. High purity ODNs were obtained 
in good yields 
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3.1 Introduction 
Synthetic oligodeoxynucleotides (ODNs) and their analogs have found wide 
applications in many areas. Examples include antisense drug development,1 DNA-protein 
interactions,2 nanotechnology,3,4  bioconjugation,5 CRISPR genome editing,6 DNA damage 
and repair,7 DNA methylation and demethylation,8 DNA data storage,9 and synthetic 
biology.10 It is projected that ODN analogs that contain sensitive functional groups have 
the potential to greatly expand the scope of the applications and bring about new research 
directions. Example sensitive ODN analogs include those containing functional groups 
such as alkyl halides, benzyl halide, allyl halides, α-halo amides, esters, activated esters, 
carbonates, thioesters, tosylates, sulfonic esters, sultones,  phosphates, α,β-unsaturated 
carbonyl compounds, epoxides, aziridines, maleimides, vinyl arenes, methides, vinyl 
ethers, acetals, and hemiacetals. These groups are generally stable under typical chemical 
and biological conditions and can co-exist with functional groups of natural ODNs. 
However, they cannot survive the harsh acidic and basic conditions used in traditional 
ODN synthesis and deprotection. Therefore, traditional ODN synthesis technologies 
cannot be used to synthesize such sensitive ODNs. Some efforts have been made to address 
the problem, but limited success has been achieved.11-20 Owing to the high potential of 
modified ODNs to bring transformative impact to many research areas, it is therefore 
significant to develop synthetic technologies that can be used to install any sensitive 
functional groups that are compatible with natural ODNs into any positions of ODNs. 
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Scheme 3.1 Deprotection of ODNs assembled with 2-cyanoethyl-Dmoc and Dim-Dmoc 
phosphoramidite monomers. 
To achieve this goal, we recently introduced the 1,3‐dithian‐2‐yl-methoxycarbonyl 
function (Dmoc) as amino protection groups and cleavable linker for solid phase ODN 
synthesis.21-23 Mainly due to the concern of low efficiency of inorganic oxidizing agents to 
penetrate into the relatively hydrophobic fully protected ODNs to oxidize the dithioketals 
for deprotection and cleavage, we used the 2-cyanoethyl group for phosphate protection. 
At the end of synthesis, deprotection and cleavage were achieved in three steps. First, the 
2-cyanoethyl groups were removed with the non-nucleophilic organic base DBU in 
acetonitrile (Scheme 3.1). This converted the hydrophobic fully protected ODN 3.1 into 
the hydrophilic 3.2. The hydrophilic anionic phosphate groups were believed to be 
beneficial for the inorganic oxidizing agent in water to penetrate into ODN in the next step. 
Second, the dithioketals in 3.2 were oxidized with sodium periodate to give 3.3. This 
drastically increased the acidity of H-2 in the 1,3-dithane function. Third, after washing 
away the inorganic materials, β-eliminations were induced with the weak base aniline, and 
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the ODNs were cleaved from the solid support and fully deprotected to give 3.4. In this 
paper, we report our results on the study of the feasibility of using the Dim instead of 2-
cyanoethyl function to protect the phosphate group. ODNs synthesized with this protection 
strategy should appear as 3.5 (Scheme 1). Deprotection and cleavage can then be achieved 
in two steps by oxidation of the dithioketals to give 3.6 followed by β-elimination. Besides 
reducing one step during deprotection, another advantage is that the use of the strong base 
DBU is avoided, which is expected to expand the scope of sensitive functions that can be 
incorporated into ODNs. Indeed, our results showed that the new protecting strategy was 
feasible, and the concern of inefficient oxidation of dithioketals in the relatively 
hydrophobic 3.5 was unnecessary. Using the new Dim-Dmoc technology, ODNs including 
those that contain sensitive functions can be synthesized in good yields and high purity 
under finely tuned but reliable conditions. 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. Dim-Dmoc phosphoramidite monomers and CPG with Dmoc linker 
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Scheme 3.2  Synthesis of Dim-Dmoc phosphoramidite monomers 
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3.2 Results and Discussion 
To use the Dim-Dmoc technology to synthesize ODNs, the phosphoramidite 
monomers 3.7a-d and the solid support with Dmoc linker 3.8 were needed (Figure 3.1). 
Preparation of 3.8 was reported previously.21 The synthesis of 3.7a-d is shown in Scheme 
3.2. Compound 3.9 in toluene was reacted with commercially available 
bis(diisopropylamino)chlorophosphine (3.10) in the presence of the amine base 
diisopropylamine at room temperature overnight under an inert atmosphere.24, 25 This gave 
the intermediate 3.11, which was not isolated. A nucleoside with 5'-OH protected with a 
4,4'-dimethoxytrityl (DMTr) or trityl group and amino group protected with the Dmoc 
group (3.12) and the activator diisopropylammonium tetrazolide (3.13) were dissolved in 
DCM. The intermediate 3.11 in the supernatant was transferred via a cannula with its 
inflow end wrapped with a copper wire-secured filter paper into the solution of 3.12 and 
activator. The reaction was allowed to proceed at room temperature overnight. The crude 
product was purified with flash column chromatography without aqueous workup. Good 
to excellent yields of the Dim-Dmoc phosphoramidites 3.7a-d were obtained (Scheme 3.2). 
With the Dim-Dmoc phosphoramidites in hand, we tested the feasibility of using them as 
building blocks for ODN synthesis under weakly nucleophilic and weakly basic 
deprotection and cleavage conditions by the synthesis of the unmodified ODN 3.14a 
(Figure 3.2). CPG with a Dmoc linker (3.8) was used as the solid support.21 The 
phosphoramidites 3.7a-d were used as nucleoside monomers. The syntheses were 
conducted on a MerMade 6 DNA synthesizer using typical scripts with some 
modifications. Briefly, detritylation was achieved with 3% DCA in DCM. In coupling, 0.1 
M solutions of 3.7a-d in acetonitrile were used with 5-(ethylthio)-1H-tetrazole as activator. 
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Capping was accomplished using 2-cyanoethyl N,N,N',N'-
tetraisopropylphosphorodiamidite with the same activator for coupling. Typical conditions 
involving iodine was used for oxidation. In the last coupling step, the 5'-trityl protected 
instead of 5'-DMTr protected phosphoramidite 3.7e was used to incorporate the nucleotide 
at the 5'-end of the ODN. The synthesis of 3.7e is shown in Scheme 3.2 and was similar as 
the synthesis of 3.7a-d. Deprotection and cleavage of ODN was achieved in two steps 
(Scheme 3.3). First, the dithioketal bonds in the Dim and Dmoc functions in the fully 
protected ODN 3.15 were oxidized with a solution of sodium periodate in water at room 
temperature to give 3.16. Excess oxidizing agents and other materials were simply removed 
by washing the CPG with water. Second, the CPG was suspended in a solution of aniline 
in water. This induced β-eliminations of the oxidized Dim and Dmoc functions in 3.16, 
which cleaved the ODN from CPG and gave ODN 3.17. At this stage, 3.17 was fully 
deprotected except for a trityl tag at its 5'-end, which was desirable for the purpose of 
assisting RP HPLC purification of the ODN. To remove small organic molecules, the ODN 
was precipitated from water with butanol. The residue was injected into RP HPLC to 
generate the profile of crude ODN, in which the tagged full-length ODN was well separated 
from other materials (Figure 3.3). The trityl-tagged ODN was collected and analyzed with 
HPLC giving a single peak (profile in supporting information). Removing the tag was 
achieved with 80% acetic acid, which is the typical condition for detritylation of DMTr-
tagged ODNs. The ODN with trityl tag removed was purified with RP HPLC, and the 
purified fully deprotected ODN was analyzed again with RP HPLC. As shown in Figure 
3.3, a single sharp peak was observed. The pure ODN 3.14a was analyzed with MALDI-
TOF MS. Correct molecular peak was found (Figure 3.4). The amount of pure ODN 
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obtained was estimated by UV, and an OD260 of 2.15 was given for a 0.52 µmol synthesis 
(supporting information). Besides 3.14a, two additional unmodified ODNs 3.14b-c were 
synthesized and analyzed under similar conditions to further confirm the viability of the 
new technology. Analysis data are in supporting information. 
Scheme 3.3 ODN deprotection and cleavage. 
 
Next, we tested the feasibility of the Dim-Dmoc technology for the synthesis of sensitive 
ODNs by incorporating the ester and alkyl chloride functions into ODNs. The synthesis of 
the required Dim phosphoramidite monomers (3.18a-b) is shown in Scheme 3.4. The 
known compound 3.19 was converted to 3.24 in five simple steps. Compounds 3.19 and 
3.24 were then converted to their corresponding Dim phosphoramidites 3.18a-b, 
respectively using the similar conditions for the synthesis of 3.7a-e. The phosphoramidites 
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3.18a-b contain the sensitive ethyl ester and alkyl chloride groups, which are sensitive to 
traditional ODN cleavage and deprotection conditions involving heating in a concentrated 
ammonium hydroxide solution. The alkyl chloride is also sensitive to bases via β-
elimination. The ODN sequences 3.14d-g (Figure 3.2) were selected for the studies, of 
which the long chain chloroalkane-containing 3.14f-g could provide a means to prepare 
protein-DNA conjugates via the bioorthogonal reaction between haloalkane dehalogenase 
and chloroalkanes.26 The ODNs were synthesized under the same conditions described for 
the synthesis of unmodified ODNs. Deprotection and cleavage conditions were also the 
same. RP HPLC profiles of crude and pure ODNs 3.14d and 3.14f are in Figure 3.3. Their 
MALDI-TOF MS spectra are in Figure 3.4. All other analytical data are in supporting 
information. The data proved that the Dim-Dmoc technology can be used to synthesize the 
sensitive ODNs that contain the ester and alkyl chloride functionalities in high yields and 
purity.  
 
 
 
 
 
 
Figure 3.2. ODN sequences 
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Figure 3.3. HPLC profiles. In the profiles of crude ODNs, the major peak at around 40 
minutes is the fully deprotected ODN with a 5'-trityl tag. In the profiles of pure ODNs, 
the single sharp peak is the fully deprotected ODN without a 5'-trityl tag. 
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Figure 3.4. MALDI-TOF MS of ODNs 3.14a, 3.14d and 3.14f. 
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Scheme 3.4. Synthesis of Dim phosphoramidites 3.18a-b that contain sensitive groups. 
 
The use of the Dim group to protect the phosphate groups in ODN synthesis has two 
advantages over the method in our previous reports,21-23 in which the 2-cyanoethyl group 
was used. First, the number of steps in deprotection and cleavage is reduced from three to 
two, which significantly simplifies the procedure. Second, the use of the strong organic 
base DBU to remove the 2-cyanoethyl groups is avoided, which can expand the scope of 
sensitive groups to be incorporated into ODNs. Earlier, our decision to use the 2-cyanoethyl 
group instead of Dim for phosphate protection was based on several considerations 
including the complex nature of chemical ODN synthesis, difficulty to make highly pure 
Dim phosphoramidites (3.7a-d) required for repeated use in a multistep linear synthesis 
with satisfactory overall yield, and as mentioned earlier the concern of inefficient oxidation 
of dithioketals during ODN deprotection and cleavage. ODN synthesis is a highly complex 
process. After careful engineering by many chemists in several decades, the standard 
procedure is robust. However, slight modification of the procedure can cause significant 
problems, and those problems are usually very difficult to diagnose and address. For the 
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synthesis of Dim phosphoramidites 3.7a-d, it was a concern too. Unlike their 2-cyanoethyl 
counterparts, which can be synthesized using the commercially available 2-cyanoethyl-
N,N,N',N'-tetraisopropylphosphordiamidite as the phosphitylation agent, these compounds 
have to be synthesized using a new phosphitylation agent such as 3.11, which is difficult 
to prepare and purify. For concerns on the inefficiency of oxidation of the dithioketals 
during ODN deprotection and cleavage, the fully protected ODNs on the CPG are relatively 
hydrophobic; which excludes the use of oxidizing agents that can only function in water. 
However, to oxidize multiple dithioketals with complete conversion, the reaction must be 
highly efficient, and thus the broadness of the scope of oxidizing agents that can be tested 
is important for the technology to be successful. Therefore, during our initial studies, we 
chose to use the much simpler and well established 2-cyanoethyl protection chemistry. 
Indeed, we met many problems during the studies. For example, at the beginning of the 
project, our RP HPLC profiles were messy. After testing many hypotheses, we finally 
found that one of the problems was cap exchange, in which the Dmoc groups used for 
amino protection were replaced by acyl groups during capping involving using reagents 
such as acetic anhydride under traditional capping conditions. This was counter intuitive 
because the donation of the lone pair of electrons from the oxygen atom to the carbonyl 
carbon in the Dmoc function would make the Dmoc protection more stable than acyl 
protections. Once the problem was diagnosed, it was solved elegantly by using the 
phosphorylation chemistry instead of the acylation chemistry for capping. The synthesis of 
3.7a-d and making them highly pure for ODN synthesis were indeed difficult too. We 
screened many conditions and were finally able to identify a procedure involving using 
toluene as the solvent and diisopropylamine as base to prepare the phosphitylation agent 
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3.11. With toluene and diisopropylamine, 3.11 was soluble while the side product 
diisopropylammonium salt was not. This allowed us to obtain 3.11 with sufficient purity 
for the phosphitylation reaction without aqueous workup and chromatography 
purification.24, 25 Of surprise was that the oxidation of dithioketals in the fully protected 
relatively hydrophobic 3.5 during ODN deprotection and cleavage was achieved with ease 
using the aqueous solution of sodium periodate. The efficiency was similar to the oxidation 
of 3.2, which was highly hydrophilic due to the anionic phosphate groups. Probably, the 
fully protected ODNs had limited but sufficient solubility in water for the oxidation 
reaction to occur at the outermost sphere of the ODN coated CPG. Once the dithioketals in 
the outermost layer were oxidized, the solubility increased, and the reaction   gradually 
penetrated into the inner layer and all dithioketals were oxidized efficiently. However, one 
observation still puzzles us. We synthesized a simple model oligosulfoxide compound, 
which contained six sulfoxide groups. We thought that this compound would be highly 
soluble in water. To our surprise, it was almost insoluble or had very limited solubility in 
any solvents including water.27 During the development of the technology, we found that 
using the trityl group instead of the DMTr group as the 5'-tag to assist RP HPLC 
purification was needed. When DMTr group was used, the tag was easy to fall off in the 
sodium periodate oxidation step. The trityl group was able to survive the conditions. 
Importantly, we found that the trityl group could be removed efficiently with 80% acetic 
acid under similar conditions used for removing the DMTr group after HPLC purification, 
which was inconsistent to the report that deprotection of trityl group required two days at 
room temperature.28 One concern on developing the Dim-Dmoc technology was the 
difficulty to identify selective oxidative conditions for the oxidation of phosphite triesters 
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to phosphate triesters during ODN synthesis and for oxidation of dithioketals during 
deprotection and cleavage. For the former, we were gratified to find that the standard iodine 
oxidation conditions were highly selective, and premature oxidation of the dithioketals had 
never been observed. For the latter, the sodium periodate solution elegantly accomplished 
an otherwise highly challenging task, which required highly efficient and selective 
oxidation of the multiple dithioketal groups while not damaging the ODNs via oxidation 
of the nucleobases and other portions of the molecules. 
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3.3 Conclusion 
In conclusion, a new method for solid phase ODN synthesis has been developed. The 
method uses Dim for phosphate protection, Dmoc for amino protection, and a Dmoc linker 
for anchoring the ODN to solid support. With the new protection and linking strategy, ODN 
deprotection and cleavage can be achieved under oxidative conditions without using any 
strong bases and nucleophiles. Therefore, the new method is suitable for the synthesis of 
ODN analogs containing base labile and electrophilic groups, a task that cannot be 
accomplished or is highly challenging to accomplish using traditional technologies. We 
expect that the new method will be able to provide a wide range of sensitive ODN analogs 
to researchers in research areas such as antisense drug development, DNA-protein 
interaction studies, nanotechnology  and bioconjugation. 
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3.4 Experimental Section 
General information:  
All reactions were performed in oven-dried glassware under argon using standard Schlenk 
techniques. Reagents and solvents available from commercial sources were used as 
received unless otherwise noted. Lcaa-CPG (pore size 497 Å) was purchased from Prime 
Synthesis. THF, toluene, and CH2Cl2 were dried using an Innovative Technology Pure-
Solv™ system. Pyridine and diisopropylamine were distilled over CaH2 under nitrogen. 
Compounds 3.12a-e were prepared according to reported procedure.21, 22, 29 Thin layer 
chromatography (TLC) was performed using Sigma-Aldrich TLC plates, silica gel 60F-
254 over glass support, 250 μm thickness. Flash column chromatography was performed 
using SiliCycle silica gel, particle size 40-63 μm. 1H, 13C and 31P NMR spectra were 
measured on a Varian UNITY INOVA spectrometer at 400, 100 and 162 MHz, 
respectively; chemical shifts (δ) were reported in reference to solvent peaks (residue CHCl3 
at δ 7.24 ppm for 1H and CDCl3 at δ 77.00 ppm for 13C) and to H3PO4 (δ 0.00 ppm for 31P). 
HRMS was obtained on a Thermo HR-Orbitrap Elite Mass Spectrometer. LRMS was 
obtained on a Thermo Finnigan LCQ Advantage Ion Trap Mass Spectrometer. MALDI-
TOF MS were obtained on Bruker’s microflex™ LRF MALDI-TOF System. ODNs were 
synthesized on a MerMade 6 solid phase synthesizer. RP HPLC was performed on a 
JASCO LC-2000Plus System: pump, PU-2089Plus Quaternary Gradient; detector UV-
2075Plus. A C-18 reversed phase analytical column (5 μm diameter, 100 Å, 250 × 3.20 
mm) was used. Solvent A: 0.1 M triethylammonium acetate, 5% acetonitrile. Solvent B: 
90% acetonitrile. All profiles were generated by detecting absorbance at 260 nm using the 
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linear gradient solvent system: solvent B (0%-45%) in solvent A over 60 min followed by 
solvent B (45%-100%) in solvent A over 20 min at a flow rate of 1.0 mL/min. 
Compound 3.7a: 
To a solution of 3.9 (1.57 g, 10.48 mmol, 1.5 eq.) and freshly distilled diisopropyl amine 
(9.85 mL, 69.9 mmol, 10 eq.) in dry toluene (25 mL) was added 
bis(diisopropylamino)chlorophosphine (3.10, 2.80 g, 10.48 mmol, 1.5 eq.) at rt under 
argon. After stirring overnight, the intermediate 3.11 in the supernatant was transferred into 
a solution of 3.12a (3.80 g, 6.99 mmol, 1 eq.) and diisopropylammonium tetrazolide (3.13, 
1.80 g, 10.48 mmol, 1.5 eq.) in dry DCM (50 mL) via a cannula with its inflow end wrapped 
with a copper wire-secured filter paper.  The reaction mixture was stirred overnight, and 
then concentrated to dryness. The residue was loaded directly on a column for flash column 
chromatography (SiO2, 1:1 hexanes/EtOAc with 5% Et3N).  Compound 3.7a was obtained 
as a white foam (5.04 g, 88%): Mixture of two diastereoisomers; Rf = 0.2 and 0.3 (SiO2, 
1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.04-1.16 (m, 12H), 1.38 (s, 3H), 1.77-
1.87 (m, 1H), 1.96-2.07 (m, 1H), 2.28-2.42 (m, 1H), 2.45-2.58 (m, 1H), 2.60-2.69 (m, 2H), 
2.65-2.84 (m, 4H), 3.29-3.46 (m, 2H), 3.47-3.69 (m, 2H), 3.76 (s, 6H), 3.80-3.89 (m, 1H), 
4.04-4.23 (m, 1H), 4.74-4.77 (m, 1H), 6.38 (t, J = 5.76 Hz, 1H), 6.81 (dd, J = 8.81, 3.16 
Hz, 4H), 7.20-7.29 (m, 7H), 7.40 (d, J = 7.60 Hz, 2H), 7.60 (s, 0.5H), 7.63 (s, 0.5 H), 8.84 
(brs, 1H); 13C NMR (100 MHz, CDCl3) δ 12.1, 24.81, 24.88, 24.95, 25.0, 26.1, 26.2, 28.8 
(d, Jcp = 9.15 Hz), 29.0 (d, Jcp = 17.15 Hz), 40.5 (d, Jcp = 5.35 Hz), 40.6 (d, Jcp = 1.84 
Hz), 43.4 (d, Jcp = 3.38 Hz), 43.5 (d, Jcp = 3.41 Hz), 47.1 (d, Jcp = 7.04 Hz), 47.8 (d, Jcp 
= 6.77 Hz), 55.5, 63.3, 63.7, 64.8 (d, Jcp = 18.15 Hz), 65.0 (d, Jcp = 18.90 Hz), 73.6 (d, 
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Jcp = 15.59 Hz), 74.1 (d, Jcp = 15.19 Hz), 84.8, 85.0, 85.4 (d, Jcp = 6.69 Hz), 86.0 (d, Jcp 
= 2.83 Hz), 87.0, 87.1, 111.2, 113.4, 127.2, 128.1, 128.4, 130.4, 135.5, 135.6, 135.7, 136.0, 
136.1, 144.5, 144.6, 150.4, 158.8, 164.0; 31P NMR (162 MHz, CDCl3) δ 149.4, 149.6 
ppm; HRMS (ESI) m/z calcd for C42H55N3O8PS2 [M+H]
+ 824.3168, found 824.3170.  
Compound 3.7b: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 1:1 
hexanes/EtOAc with 5% Et3N) gave 3.7b as a white foam (1.25 g, 52%): Mixture of two 
diastereoisomers; Rf = 0.2 and 0.3 (SiO2, 1:2 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3) 
δ 1.04-1.26 (m, 12H), 1.72-1.84 (m, 2H), 1.90-2.09 (m, 4H), 2.30-2.47 (m, 2H), 2.59-2.74 
(m, 6H), 2.85-2.93 (m, 2H), 3.39-3.60 (m, 4H), 3.61-3.89 (m, 1H), 3.77 (s, 6H), 3.91-4.16 
(m, 2H), 4.17-4.22 (m, 1H), 4.40-4.49 (m, 1H), 6.18-6.22 (m, 1H), 6.81 (d, J = 7.4 Hz, 4H), 
7.18-7.29 (m, 7H), 7.7.39 (d, J = 7.60 Hz, 2H), 8.27-8.29 (m, 0.5H), 8.34-8.35 (m, 0.5H); 
13C NMR (100 MHz, CDCl3) δ 23.3 (d, Jcp = 2.21 Hz), 23.4 (d, Jcp = 1.59 Hz), 24.85, 
24.89, 24.92, 24.98, 25.1, 25.7, 25.9, 26.1, 26.2, 27.5, 27.6, 28.7 (d, Jcp = 13.00 Hz), 29.1 
(d, Jcp = 21.54 Hz), 41.2 (d, Jcp = 5.73 Hz), 41.5, 43.1, 43.4, 43.5, 45.4, 45.5, 47.1 (d, Jcp 
= 6.88 Hz), 47.7 (d, Jcp = 8.28 Hz), 55.5, 61.9, 62.4, 64.7 (d, Jcp = 19.91 Hz), 64.8 (d, Jcp 
= 18.5 Hz), 65.8, 65.9, 71.4 (d, Jcp = 9.27 Hz), 71.9 (d, Jcp = 10.13 Hz), 85.2 (d, Jcp = 
7.30 Hz), 86.1, 87.0, 94.5, 113.4, 127.2, 128.1, 128.4, 130.2, 130.3, 135.5, 135.6, 135.7, 
135.8, 144.3, 144.4, 144.9, 145.0, 151.9, 155.0, 158.7, 161.9, 162.0; 31P NMR (162 MHz, 
CDCl3) δ 149.2, 149.5; HRMS (ESI) m/z calcd for C47H62N4O9PS4 [M+H]+ 985.3137, 
found 985.3130.  
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Compound 3.7c: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 1:1 
hexanes/EtOAc with 5% Et3N) gave 3.7c as a white foam (1.30 g, 68%): Mixture of two 
diastereoisomers; Rf = 0.3 and 0.4 (SiO2, 1:2 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3) 
δ 1.09-1.25 (m, 12H), 1.75-1.84 (m, 2H), 1.95-2.04 (m, 4H), 2.59-2.75 (m, 6H), 2.87-2.98 
(m, 4H), 3.31-4.00 (m, 4H), 3.75 (s, 6H), 4.00 (t, J = 6.48 Hz, 0.5H), 4.05-4.18 (m, 1.5H), 
4.21-4.27 (m, 0.5H), 4.30-4.39 (m, 0.5H), 4.55 (d, J = 7.1 Hz, 2H), 4.80-4.88 (m, 1H), 6.46 
(t, J = 6.5 Hz, 1H), 6.74-6.77 (m, 4H), 7.14-7.30 (m, 7H), 7.36 (d, J = 11.96 Hz, 2H), 8.16 
(s, 0.5H), 8.19 (s, 0.5H), 8.68 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 23.27 (d, Jcp = 2.57 
Hz), 23.33 (d, Jcp = 2.00 Hz), 24.86, 24.92, 24.99, 25.8, 26.1, 27.6, 28.8 (d, Jcp = 11.54 
Hz), 29.1 (d, Jcp = 14.52 Hz), 40.1 (d, Jcp = 14.77 Hz), 43.3, 43.4, 43.5, 45.45, 45.51, 47.2 
(d, Jcp = 7.48 Hz), 47.7 (d, Jcp = 7.55 Hz), 55.5, 63.4, 63.7, 64.7 (d, Jcp = 13.84 Hz), 65.4 
(d, Jcp = 18.48 Hz), 65.6, 73.9 (d, Jcp = 13.71 Hz), 74.0 (d, Jcp = 15.26 Hz), 84.8, 85.1, 
85.9, 86.4, 86.6, 86.7, 113.3, 122.6, 127.0, 128.0, 128.3, 130.2, 135.78, 135.85, 141.6, 
141.7, 144.67, 144.72, 149.2, 150.5, 151.06, 151.12, 152.8, 158.6; 31P NMR (162 MHz, 
CDCl3) δ 149.4, 149.6; HRMS (ESI) m/z calcd for C48H62N6O8PS4 [M+H]+ 1009.3249, 
found 1009.3255.  
Compound 3.7d: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 8:1:1 
EtOAc/ACN/Et3N) gave 3.7d as a white foam (1.30 g, 68%): Mixture of two 
diastereoisomers; Rf = 0.2 and 0.3 (SiO2, 8:1:1 EtOAc/ACN/Et3N). 
1H NMR (400 MHz, 
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CDCl3) δ 1.07-1.16 (m, 12H), 1.77-1.86 (m, 2H), 1.97-2.08 (m, 4H), 2.59-2.94 (m, 10H), 
3.25-3.31 (m, 2H), 3.52-3.58 (m, 2H), 3.75 (s, 6H), 3.58-4.21 (m, 2.5H), 4.29-4.32 (m, 
0.5H), 4.50 (d, J = 3.48 Hz, 1H), 4.52 (d, J = 3.44 Hz, 1H), 4.72-4.81 (m, 1H), 6.18-6.23 
(m, 1H), 6.72-6.78 (m, 4H), 7.16-7.30 (m, 7H), 7.37 (d, J = 7.04 Hz, 1H), 7.39 (d, J = 7.76 
Hz, 1H), 7.8 (s, 0.5H), 7.82 (s, 0.5H); 13C NMR (100 MHz, CDCl3) δ 24.86, 24.91, 24.94, 
24.98, 25.6, 26.1, 27.1, 28.88 (d, Jcp = 11.11 Hz), 29.16 (d, Jcp = 8.47 Hz), 39.9, 42.5, 
43.4, 43.5, 47.2 (d, Jcp = 6.85 Hz), 47.6 (d, Jcp =7.36 Hz), 55.5, 63.6, 63.9, 64.8 (d, Jcp = 
6.59 Hz), 65.0 (d, Jcp = 6.47 Hz), 66.0, 73.9 (d, Jcp = 11.09 Hz), 74.1 (d, Jcp = 16.48 Hz), 
84.3, 84.4, 85.7 (d, Jcp =6.62 Hz), 86.2 (d, Jcp = 2.85 Hz), 86.6, 113.3, 121.6, 127.0, 128.0, 
128.3, 128.4, 130.18, 130.24, 135.8, 135.9, 137.4, 137.5, 144.6, 144.7, 146.3, 148.30, 
148.32, 153.11, 153.13, 155.7, 158.6; 31P NMR (162 MHz, CDCl3) δ 148.9, 149.6; HRMS 
(ESI) m/z calcd for C48H62N6O9PS4 [M+H]
+ 1025.3198, found 1025.3205.  
Compound 3.7e: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 1:1 
hexanes/EtOAc with 5% Et3N) gave 3.7e as a white foam (233 mg, 87%): Mixture of two 
diastereoisomers; Rf = 0.2 and 0.3 (SiO2, 1:1 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3) 
δ 1.04-1.27 (m, 12H), 1.40 (s, 3H), 1.78-1.86 (m, 1H), 1.96-2.05 (m, 1H), 2.29-2.98 (m, 
8H), 3.30-3.99 (m, 5H), 4.05-4.25 (m, 1H), 4.74-4.81 (m, 1H), 6.38 (t, J = 7.1 Hz, 1H), 
7.18-7.35 (m, 9H), 7.36-7.45 (m, 6H), 7.56 (s, 0.5H), 7.60 (s, 0.5H), 9.11 (brs, 1H); 13C 
NMR (100 MHz, CDCl3) δ 12.1, 24.84, 24.88, 24.91, 24.95, 25.01, 26.1, 26.2, 28.8 (d, Jcp 
= 8.40 Hz), 29.0 (d, Jcp = 17.34 Hz), 40.4 (d, Jcp = 5.12 Hz), 40.6, 43.4, 43.5, 47.0 (d, Jcp 
= 7.16 Hz), 47.5 (d, Jcp = 7.43 Hz), 63.5, 63.9, 64.8 (d, Jcp = 17.88 Hz), 65.0 (d, Jcp = 
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18.41 Hz), 73.6 (d, Jcp = 15.28 Hz), 73.9 (d, Jcp = 14.43 Hz), 84.8, 85.0, 85.3 (d, Jcp = 
6.74 Hz), 85.9, 87.55, 87.61, 111.1, 111.2, 127.5, 128.1, 128.9, 135.9, 136.0, 143.5, 143.6, 
150.5, 164.1; 31P NMR (162 MHz, CDCl3) δ 149.4, 149.7; HRMS (ESI) m/z calcd 
C40H51N3O6PS2 [M+H]
+ 764.2956, found 764.2960.  
Compound 3.20: 
To a suspension of lithium aluminum hydride (1.15 g, 30.29 mmol, 5 eq.) in dry THF (25 
mL) was added a solution of 3.19 (3.15 g, 6.06 mmol, 1 eq.) in dry THF (50 mL) dropwise 
via cannula at 0 °C under nitrogen. The reaction mixture was stirred for 3 h, and then 
quenched by dropwise addition of H2O (1.15 mL), 15% NaOH (1.15 mL), and H2O (3.45 
mL), sequentially. The white precipitate was removed by filtration over Celite. The filtrate 
was concentrated to dryness. Flash column chromatography (SiO2, 1:1 hexanes/EtOAc 
with 5% Et3N) gave 3.20 as a colorless oil (2.45 g, 80%): Rf = 0.2 (SiO2, 1:1 
hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.20-1.42 (m, 14H), 1.53 (p, J = 5.80 Hz, 
2H), 1.65 (brs, 1H), 2.45 (brs, 1H), 3.02 (dd, J = 9.28, 7.56 Hz, 1H), 3.16 (dd, J = 9.60, 
3.56 Hz, 1H), 3.59 (t, J = 6.6 Hz, 2H), 3.73-3.75 (m, 1H), 3.76 (s, 6H), 6.82 (d, J = 8.9 Hz, 
4H), 7.20 (tt, J = 7.40, 1.16 Hz, 1H), 7.28 (t, J = 7.24 Hz, 2H), 7.32 (d, J = 8.96 Hz, 2H), 
7.43 (d, J = 9.64 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 25.8, 26.1, 29.72, 29.78, 29.8, 
29.9, 33.0, 33.7, 55.5, 63.2, 67.9, 71.2, 86.2, 113.3, 126.9, 127.9, 128.3, 130.2, 136.2, 
145.0, 158.5; HRMS (ESI) m/z calcd for C32H43O [M+H]
+ 507.3110, found 507.3122.  
Compound 3.21: 
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To a solution of 3.20 (2.06 g, 4.07 mmol, 1 eq.) in freshly distilled pyridine (50 mL) was 
added TsCl (0.814 g, 1.05 eq.) at 0 °C under nitrogen. The mixture was stirred at the same 
temperature for 8 h. The majority of pyridine was evaporated on a rotary evaporator under 
vacuum generated by an oil pump. The remaining content was poured into a separatory 
funnel containing 5% NaHCO3 (100 mL) and extracted with EtOAc (50 mL × 3). The 
extracts were dried over anhydrous Na2SO4, filtered, and concentrated. Flash column 
chromatography (SiO2, 2:1 hexanes/EtOAc with 5% Et3N) gave 3.21 as a pale-yellow oil 
(1.37 g, 51%): Rf = 0.4 (SiO2, 1:1 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3) δ 1.12-
1.41 (m, 14H), 1.61 (p, J = 6.72 Hz, 2H), 2.42 (s, 3H), 3.01 (t, J = 9.16 Hz, 1H), 3.16 (dd, 
J = 9.40, 3.28 Hz, 1H), 3.70-3.74 (m, 1H), 3.76 (s, 6H), 4.00 (t, J = 6.5 Hz, 2H), 6.81 (d, J 
= 8.8 Hz, 4H), 7.20 (t, J = 7.12 Hz, 1H), 7.26 (t, J = 4.80 Hz, 2H), 7.31 (d, J = 8.80 Hz, 
6H), 7.43 (d, J = 7.28 Hz, 2H), 7.77 (d, J = 8.32 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 
21.9, 25.6, 25.7, 29.1, 29.2, 29.60, 29.67, 29.8, 33.6, 55.5, 67.8, 70.9, 71.2, 86.2, 113.3, 
126.9, 127.9, 128.3, 129.9, 130.2, 133.4, 136.2, 144.7, 145.0, 158.5; HRMS (ESI) m/z 
calcd for C39H49O7S [M+H]
+ 661.3199, found 661.3204.  
Compound 3.22: 
To a solution of 3.21 (6.78 g, 10.28 mmol, 1 eq.) in dry DMSO (25 mL) was added KCN 
(0.802 g, 12.34 mmol, 1.2 eq.) at rt under nitrogen. The reaction mixture was stirred at 60 
°C overnight. After cooling to rt, EtOAc (100 mL) was added, and the organic phase was 
washed with brine (100 ml), dried over anhydrous Na2SO4, filtered, and concentrated. 
Flash column chromatography (SiO2, 4:1 hexanes/EtOAc with 5% Et3N) gave 3.22 as a 
colorless oil (4.20 g, 79%): Rf = 0.2 (SiO2, 4:1 hexanes/EtOAc); 
1H NMR (400 MHz, 
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CDCl3) δ 1.22-1.26 (m, 10H), 1.37-1.42 (m, 4H), 1.61 (p, d = 7.12 Hz, 2H), 2.27 (t, J = 
7.12 Hz, 2H), 2.41 (brs, 1H), 3.02 (dd, J = 9.24, 7.52 Hz, 1H), 3.16 (dd, J = 9.32, 3.32 Hz, 
1H), 3.76 (s, 6H), 6.81 (d, J = 8.9 Hz, 4H), 7.20 (t, J = 7.36 Hz, 1H), 7.28 (t, J = 7.76 Hz, 
2H), 7.32 (d, J = 8.48 Hz), 7.43 (d, J = 8.2 Hz); 13C NMR (100 MHz, CDCl3) δ 17.4, 25.7, 
25.8, 28.9, 29.0, 29.5, 29.7, 29.9, 33.7, 55.5, 67.9, 71.2, 86.3, 113.3, 120.0, 126.9, 127.95, 
127.98, 128.3, 130.2, 136.3, 145.0, 158.6; HRMS (ESI) m/z calcd for C33H42NO4 [M+H]
+ 
516.3113, found 516.3120.  
Compound 3.23: 
To a suspension of lithium aluminum hydride (1.55 g, 40.8 mmol, 5 eq.) in dry THF (50 
mL) was added a solution of 3.22 (4.20 g, 8.16 mmol, 1 eq.) in dry THF (50 mL) dropwise 
via cannula at 0 °C under nitrogen. The mixture was stirred overnight while warming to rt 
gradually. The reaction was then quenched by dropwise addition of H2O (1.55 mL), 15% 
aq. NaOH (1.55 mL), and H2O (4.65 mL), sequentially. The white precipitate was removed 
by filtration over Celite and the filtrate was concentrated to dryness. Flash column 
chromatography (SiO2, 8:1:1 EtOAc/MeOH/Et3N) gave 3.23 as a pale-yellow oil (2.50 g, 
60%): Rf = 0.2 (SiO2, 8:1:1 EtOAc/MeOH/Et3N); 
1H NMR (400 MHz, CDCl3) δ 1.15-1.49 
(m, 18H), 2.11 (brs, 2H), 2.67 (t, J = 7.08 Hz, 2H), 2.99 (dd, J = 9.08, 7.68 Hz, 1H), 3.14 
(dd, J = 9.28, 3.12 Hz, 1H), 3.70-3.73 (m, 1H), 3.77 (s, 6H), 6.81 (d, J = 8.84 Hz, 4H), 7.19 
(t, J = 6.56 Hz, 1H), 7.27 (t, J = 7.16 Hz, 2H), 7.30 (d, J = 8.64 Hz, 4H), 7.41 (d, J = 7.44 
Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 25.8, 27.2, 29.7, 29.82 (2C), 29.88, 29.9, 33.7 
(2C), 42.4, 55.5, 67.9, 71.2, 86.3, 113.3, 126.9, 128.0, 128.3, 130.2, 136.2, 145.0, 158.6; 
HRMS (ESI) m/z calcd for C33H46NO4 [M+H]
+ 520.3426, found 520.3429.  
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Compound 3.24: 
To a solution of 3.23 (220 mg, 0.423 mmol, 1 eq.) and triethylamine (88 µL, 0.635 mmol, 
1.5 eq.) in dry DCM (15 mL) was added 6-chlorohexanoyl chloride (0.051 mL, 0.423 
mmol, 1 eq.) at -78 °C under nitrogen. The mixture was stirred for 1 h while warming to rt 
slowly. Water (15 mL) was added and the organic contents were extracted with DCM (15 
mL × 3). The extracts were combined and dried over anhydrous Na2SO4, filtered, and 
concentrated. Flash column chromatography (SiO2, 2:1 hexanes/EtOAc with 5% Et3N) 
gave 3.24 as a pale-yellow oil (0.134 g, 49%): Rf = 0.5 (SiO2, 1:1 hexanes/EtOAc); 
1H 
NMR (400 MHz, CDCl3) δ 1.19-1.51 (m, 20H), 1.64 (p, J = 8.84 Hz, 2H), 1.75 (p, J = 6.68 
Hz, 2H), 2.14 (t, J = 7.36 Hz, 2H), 2.35 (brs, 1H), 3.00 (dd, J = 9.28, 7.60 Hz, 1H), 3.14 
(dd, J = 9.32, 3.32 Hz, 1H), 3.20 (q, J = 7.08 Hz, 2H), 3.50 (t, J = 6.60 Hz, 2H), 3.70-3.74 
(m, 1H), 3.76 (s, 6H), 5.49 (brs, 1H), 6.80 (d, J = 8.92 Hz, 4H), 7.19 (tt, J = 7.20, 2.12 Hz, 
1H), 7.26 (t, J = 7.76 Hz, 2H), 7.30 (d, J = 8.80 Hz, 4H), 7.41 (d, J = 8.72 Hz, 2H); 13C 
NMR (100 MHz, CDCl3) δ 25.3, 25.8, 26.8, 27.2, 29.6, 29.77, 29.79 (2C), 29.89, 29.97, 
32.6, 33.7, 36.9, 39.8, 45.1, 55.5, 67.9, 71.2, 86.3, 113.3, 126.9, 127.9, 128.3, 130.2, 136.3, 
145.0, 158.6, 172.6; HRMS (ESI) m/z calcd for C39H55ClNO5 [M+H]
+ 652.3768, found 
652.3770.  
Compound 3.18a: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 9:1 
hexanes/EtOAc with 5% Et3N) gave 3.18a as a colorless oil (412 mg, 79%): Mixture of 
two diastereoisomers; Rf = 0.6 and 0.7 (SiO2, 3:1 hexanes/EtOAc); 
1H NMR (400 MHz, 
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CDCl3) δ 1.05 (d, J = 6.76 Hz, 3H), 1.11-1.35 (m, 23H), 1.45-1.79 (m, 3H), 1.79-1.95 (m, 
1H), 1.95-2.12 (m, 1H), 2.259 (t, J = 7.68 Hz, 1H), 2.263 (t, J = 7.48 Hz, 1H), 2.57-2.68 
(m, 1H), 2.69-2.89 (m, 3H), 2.96 (q, J = 2.96 Hz, 1H), 3.06 (q, J = 5.76 Hz, 1H), 3.22 (q, J 
= 5.20 Hz, 1H), 3.22 (q, J = 5.04 Hz),  3.47-3.65 (m, 2H), 3.65-3.80 (m, 1H), 3.766 (s, 3H), 
3.773 (s, 3H), 3.84-3.92 (m, 1H), 3.92-4.05 (m, 1H), 4.11 (q, J = 7.12 Hz, 2H), 4.10-4.21 
(m, 1H), 6.78 (d, J = 11.72 Hz, 2H), 6.81 (d, J = 7.48 Hz, 2H), 7.13-7.21 (m, 1H), 7.24 (t, 
J = 7.88 Hz, 1H), 7.26 (t, J = 7.20 Hz, 1H), 7.33 (d, J = 8.64 Hz, 2H), 7.35 (dd, J = 8.04, 
1.60 Hz, 2H), 7.45 (d, J = 5.08 Hz, 1H), 7.46 (d, J = 5.24 Hz, 1H); 13C NMR (100 MHz, 
CDCl3) δ 14.6, 24.84, 24.86, 24.91, 24.94, 25.00, 25.04, 25.07, 25.11, 25.17, 25.31, 25.34, 
25.39, 26.30, 26.34, 28.6 (d, Jcp = 7.00 Hz), 28.9 (d, Jcp = 8.96 Hz), 29.47, 29.51, 29.59, 
29.72, 29.76, 29.91, 30.02, 33.76, 33.9 (d, Jcp = 6.28 Hz), 34.7, 43.2 (d, Jcp = 4.18 Hz), 
43.4 (d, Jcp = 4.01 Hz), 46.9 (d, Jcp = 5.52 Hz), 47.3 (d, Jcp = 6.98 Hz), 55.5, 60.4, 64.9 
(d, Jcp = 7.38 Hz), 65.1 (d, Jcp = 18.48 Hz), 66.3 (d, Jcp = 1.82 Hz), 66.4 (d, Jcp = 3.34 
Hz), 73.7 (d, Jcp = 14.99 Hz), 74.3 (d, Jcp = 18.69 Hz), 85.9, 113.1, 126.7, 127.8, 128.45, 
128.53, 130.30, 130.37, 136.6, 136.7, 145.3, 145.4, 158.4, 174.0; 31P NMR (162 MHz, 
CDCl3) δ 149.0, 149.2; HRMS (ESI) m/z calcd for C45H67NO7PS2 [M+H]+ 828.4096, 
found 828.4099.  
Compound 3.18b: 
The same procedure for 3.7a was used. Flash column chromatography (SiO2, 1:1 
hexanes/EtOAc with 5% Et3N) gave 3.18b as a pale-yellow oil (294 mg, 86%): Mixture of 
two diastereoisomers; Rf = 0.2 and 0.3 (SiO2, 1:1 hexanes/EtOAc); 
1H NMR (400 MHz, 
CDCl3) δ 1.03 (d, J = 6.80 Hz, 2H), 1.10-1.35 (m, 22H), 1.40-1.51 (m, 4H), 1.56-1.69 (m, 
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4H), 1.77 (p, J = 7.12 Hz), 1.81-1.94 (m, 1H), 1.95-2.10 (m, 3H), 2.15 (t, J = 7.44 Hz, 2H), 
2.56-3.15 (m, 6H), 3.21 (t, J = 6.80 Hz, 1H), 3.22 (t, J = 6.52 Hz, 1H), 3.52 (t, J = 6.64 Hz, 
2H), 3.55-4.18 (m, 4H), 3.76 (s, 1H), 3.77 (s, 3H), 4.35-4.57 (m, 2H), 5.47 (brs, 1H), 6.78 
(d, J  = 8.84 Hz, 2H), 6.80 (d, J  = 7.32 Hz, 2H), 7.13-7.21 (m, 1H), 7.21-7.28 (m, 2H), 
7.32 (dd, J = 6.52, 2.64 Hz, 2H), 7.34 (dd, J = 8.36, 1.72 Hz, 2H), 7.44 (dd, J = 5.44, 1.61 
Hz, 1H), 7.46 (dd, J = 7.20, 1.61 Hz); 13C NMR (100 MHz, CDCl3) δ 24.84, 24.86, 24.90, 
24.94, 25.00, 25.07, 25.11, 25.17, 25.28, 25.38, 25.6, 25.9, 26.1, 26.30, 26.34, 26.7, 26.8, 
27.0, 27.2, 27.3, 28.6, 28.7, 28.85, 28.88, 29.6, 29.81, 29.85, 29.88, 29.93, 29.99, 30.03, 
32.6, 33.79 (d, Jcp = 2.99 Hz), 33.86 (d, Jcp = 5.24 Hz), 36.9, 39.8, 43.2, 43.4, 45.1, 46.93 
(d, Jcp = 7.09 Hz), 47.29 (d, Jcp = 7.27 Hz), 55.5, 64.9 (d, Jcp = 17.44 Hz), 66.3 (d, Jcp = 
6.76 Hz), 74.4, 85.9, 113.2, 126.7, 127.8, 128.45, 128.53, 130.3, 136.6, 136.7, 145.3, 145.4, 
158.4, 172.6; 31P NMR (162 MHz, CDCl3) δ 149.0, 149.2; HRMS (ESI) m/z calcd for 
C50H77ClN2O6PS2 [M+H]
+ 931.4649, found 931.4650 
ODN Synthesis, Cleavage and Deprotection, and Analysis: 
All ODNs were synthesized on dT-Dmoc-CPG (26 µmol/g loading, 20 mg, 0.52 µmol) 
using a MerMade 6 Synthesizer. Dim-Dmoc phosphoramidites were used as monomers. 
The conditions suggested by synthesizer manufacturer for 1 μmol synthesis were used 
except that coupling was optionally increased from 2 to 3 times and capping was achieved 
using 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphordiamidite instead of acetic 
anhydride. Briefly, detritylation, DCA (3%, DCM), 90 sec × 2; coupling, phosphoramidite 
(3.7a-e, 3.18a or 3.18e, 0.1 M, MeCN), 5-(ethylthio)-1H-tetrazole (0.25 M, MeCN), 60 sec 
× 2 (or 3); capping, 2-cyanoethyl-N,N,N',N'-tetraisopropylphosphordiamidite (0.1 M, 
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MeCN) and 5-(ethylthio)-1H-tetrazole (0.25 M, MeCN), 60 sec × 3; oxidation, I2 (0.02 M, 
THF/pyridine/H2O, 70/20/10, v/v/v), 40 sec. For incorporating the last nucleoside, 3.7e 
instead of 3.7a was used. At the end of synthesis, the 5'-trityl group was kept on. The CPG 
was divided into 5 equal portions. One portion was gently shaken in a solution of aqueous 
NaIO4 (0.4 M, 1 mL) at rt for 3 h. The supernatant was removed with a pipette, and the 
CPG was rinsed briefly with water (1 mL × 4). To the CPG was added aqueous aniline 
solution (3%, 1 mL) and the mixture was shaken at rt for 3 h. The supernatant was 
transferred into a centrifugal tube, which was concentrated to ~100 μL. To the tube was 
added 1-butanol (900 μL). The tube was vortexed briefly and centrifuged (14.5K rpm, 5 
min). The supernatant was removed with a pipette carefully without sucking the ODN 
precipitate. The ODN was dissolved in H2O (100 μL) and ~35 μL was injected into RP 
HPLC to generate the crude ODN. Fractions of the major ODN peak at ~39 min were 
collected, concentrated to ~100 μL, and injected into HPLC to give the profile of purified 
trityl-tagged ODN. To the dried trityl-tagged ODN was added 1 mL of 80% AcOH, and 
the mixture was shaken gently at rt for 3 h. Volatiles were evaporated. The residue was 
dissolved in ~100 μL water and injected into RP HPLC. The major peak of de-tritylated 
ODN at ~21 min was collected and concentrated to dryness. The residue was the pure de-
tritylated ODN, which was dissolved in 100 μL water and injected into HPLC to generate 
the profile of pure de-tritylated ODN. The pure ODN was analyzed MALDI-TOF MS. 
Information about OD260 of the ODNs are provided in the UV spectra section of the 
Supporting Information. 
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Chapter 4 Electrophilic ODN Synthesis Using dM-
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Abstract 
Solid phase synthesis of electrophilic oligodeoxynucleotides (ODNs) was achieved using 
dimethyl Dmoc (dM-Dmoc) as amino protecting groups. Due to the high steric hindrance 
of the 2-(propan-2-ylidene)-1,3-dithiane side product from deprotection, the use of excess 
nucleophilic scavengers such as aniline to prevent Michael addition of the side product to 
the deprotected ODN during ODN cleavage and deprotection was no longer needed. The 
improved technology was demonstrated by the synthesis and characterization of five ODNs 
including three modified ones. The modified ODNs contained the electrophilic groups 
ethyl ester, α-chloroamide, and thioester. Using the technology, the sensitive groups can 
be installed at any location within the ODN sequences without using any sequence- or 
functionality-specific conditions and procedures. 
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4.1 Introduction 
After over 60 years of intensive research, the challenges for chemical 
oligodeoxynucleotide (ODN) synthesis have been considered largely overcome. 1-4 
However, this is only true for unmodified ODNs at limited synthesis scales. For modified 
ODNs that contain sensitive functionalities including those that are unstable under acidic, 
basic and strongly nucleophilic conditions, many formidable challenges remain. 2 The 
reason is that during ODN synthesis using traditional technologies, the 5'-hydroxyl group 
of nucleoside monomers is protected with the 4,4'-dimethoxytrityl (DMTr) group, which 
has to be removed with an acid in each synthetic cycle. The exo-amino groups of 
nucleosides dA, dC and dG are protected with acyl groups, the nascent ODN is anchored 
to a solid support via a base- or nucleophile-cleavable linker, and in the most widely used 
phosphoramidite technology the phosphate groups are protected with the 2-cyanoethyl 
group. These protecting groups and the linker have to be cleaved under strongly basic and 
nucleophilic conditions. As a result, many sensitive groups including acetal, hemiacetal, 
vinyl ethers, enol ethers, aldehydes, esters, activated esters, thioesters, aziridines, epoxides, 
alkyl halides, α-halocarbonyls, vinyl purines, methides and maleimides cannot or are 
difficult to be incorporated into ODNs, or cannot be installed at the desired locations in the 
ODNs. For example, to synthesize oligos that contain the epigenetically modified 5-
formylcytosine, the aldehyde group had to be protected as a cyclic acetal instead of the 
more labile acyclic acetal. 5,6 The maleimide group was incorporated into ODNs as a Diels-
Alder adduct with dimethylfuran. Besides the need of an additional step for deprotection, 
only examples of 5'-end modification were given probably due to the instability of the 
adduct under acidic conditions during ODN synthesis. 7 
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In recent years, applications of ODNs have extended to emerging areas such as 
nanotechnology, [8,9] antisense drug development, 10-12 DNA damage and repair, 13,14 DNA 
methylation and demethylation, [15-18] DNA-protein interactions, 19,20 CRISPR genome 
editing, 21-23 DNA data storage, 24,25 synthetic biology, 26 bioconjugation, 27 and others. 28-
30 These applications frequently require modified ODNs that contain a wide variety of 
functional groups including those that cannot survive known ODN synthesis, cleavage and 
deprotection conditions. To meet these demands, some work on developing new 
technologies suitable for the synthesis of sensitive ODNs has been carried out. 28,31 A 
common method is to use more labile acyl functions such as the phenoxyacetyl group for 
amino protection and as linker to enable deprotection and cleavage under milder basic 
conditions. 32 The palladium-labile allyl groups were also used for amino protection. 33,34 
The o-nitro benzyl function was used as linker to enable photo cleavage. 34 However, these 
methods are still not ideal. The phenoxyacetyl group and linker still needs nucleophilic 
cleavage. Palladium is expensive and difficult to remove from ODN. Photo irradiation can 
damage ODN. The (p-nitrophenyl)ethyl (Npe) and (p-nitrophenyl)ethyloxycarbonyl 
(Npeoc) were also explored for sensitive ODN synthesis under non-nucleophilic 
conditions. 35-38 The requirement of the strong base - DBU in aprotic solvents over long 
hours in the presence of a nucleophilic scavenger for their cleavage could limit their 
application. In addition, in some cases the sequences synthesized by the method were short 
and the yields of the ODNs were low. 35-38 In the literature, there are also examples using 
post-synthesis modifications to introduce sensitive groups to ODNs. 12 However, these 
methods are case-specific, and their procedures are usually complicated. The ODN 
synthesis method without nucleobase protection could be considered for the incorporation 
81 
of sensitive functionalities into ODNs. 39 However, a linker that can be cleaved under mild 
conditions and is suitable for the purpose has not been identified. More seriously, high 
selectivity of O-phosphitylation over N-phosphitylation, which is crucial for practical 
applications especially for the synthesis of ODNs approaching 20-mer or longer, may not 
be easy to achieve. 
 
 
 
 
 
 
 
 
Scheme 4.1. Comparison of Dmoc and dM-Dmoc as nucleobase protecting groups for 
ODN synthesis. 
 
To develop a universal technology for the synthesis of ODNs that contain a wide 
variety of sensitive functionalities, we recently reported the use of 1,3-dithian-2-yl-
methoxycabonyl (Dmoc) as protecting groups and linkers for ODN synthesis. 40,41 Due to 
the low acidity of H-2 (pKa ~31) in the Dmoc function, these groups and linkers were 
expected to be stable under ODN synthesis conditions. However, once the dithioketal in 
the group is oxidized, the acidity of H-2 (pKa ~12) is drastically increased. 42,43 Considering 
that the widely used Fmoc protecting group, of which the H-9 has a pKa of ~22, 42 can be 
readily removed with a weak base such as piperidine, we hypothesized that the oxidized 
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Dmoc groups and linkers could be cleaved under weakly basic and non-nucleophilic 
conditions via β-elimination. Indeed, we found that the deprotection and cleavage could be 
achieved by oxidation with sodium periodate followed by treating with the mild base 
aniline at room temperature. Due to the mild deprotection and cleavage conditions, we 
concluded that the technology was suitable for the synthesis of sensitive ODNs that contain 
electrophilic groups. However, at the current state of art one drawback of the technology 
is that large excess aniline has to be used as a scavenger to prevent the deprotection side 
product 4.1 from reacting with the deprotected ODNs via Michael addition. Aniline is a 
weak nucleophile, but using large excess is not ideal for a technology aimed to be 
practically and universally useful. In this paper, we report the use of dimethyl Dmoc (dM-
Dmoc), which we previously studied for alkyl and aryl amine protections, 44 in place of 
Dmoc for nucleobase protection for ODN synthesis (Scheme 4.1). Due to the steric 
hindrance of the side product 4.2 from deprotection, we found that a nucleophilic scavenger 
was no longer needed during deprotection, and the β-elimination step could be achieved 
using the non-nucleophilic weak base potassium carbonate. 
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Figure 1: dM-Dmoc phosphoramidite monomers and CPG with Dmoc linker. 
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4.2 Results and Discussion 
 
To develop the dM-Dmoc electrophilic ODN synthesis technology, the 
phosphoramidite monomers 4.3a-c and the linker 4.4 (Figure 4.1) were needed. The 
construction of linker 4.4 was reported previously. 40 The synthesis of 4.3a-c is shown in 
Scheme 4.2. The reagent 4.5 needed for protecting the exo amino groups of nucleobases 
was prepared in two steps from 1,3-dithiane (4.6) according to a procedure we reported 
previously. 44 The dC phosphoramidite monomer 4.3a was synthesized from compound 
4.9. 45 The formation of the hindered O-tert-alkyl N-arylcarbamate 4.10 was found highly 
challenging. 44,46,47 We tried many conditions and finally found that acceptable yields could 
be achieved under the highly reactive conditions involving two equivalents LDA and one 
equivalent 4.5. The silyl protecting groups were then removed with TBAF giving 
compound 4.11 in 99% yield. Tritylation of 4.11 with DMTrCl gave 4.12, which was 
phosphitylated with reagents 4.13 and 4.14 to give the target monomer 4.3a (Scheme 4.2). 
The dA phosphoramidite monomer 4.3b was synthesized similarly starting from 4.15. 48 
The amino group of 4.15 was carbamylated with 4.5 in the presence of two equivalents 
LDA to give 4.16. The silyl groups were removed, and compound 4.17 was tritylated to 
give 4.18, which was phosphitylated to give 4.3b. The dG phosphoramidite monomer 4.3c 
had to be synthesized using slightly different procedure (Scheme 4.2). The amide function 
in the nucleobase in the silyl protected nucleoside 4.19. 45 was temporarily protected with 
TBSCl to give 4.20. 49 This intermediate was not isolated and the exo amino group was 
carbamylated directly with 4.5 in the presence of two equivalents LDA giving 4.21 in 55% 
yield. The silyl protecting groups were removed to give 4.22, which was tritylated to give 
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4.23 and phosphitylated to give the target monomer 4.3c (Scheme 4.2). As will be 
discussed later, we also needed the hydrophobic phosphoramidite 4.25 for developing the 
dM-Dmoc ODN synthesis technology. The compound was simply prepared from the 
commercially available 4.24 via phosphitylation using the reagents 4.13-14 (Scheme 4.2). 
Scheme 4.2. Synthesis of compound 4.5, 44 nucleoside phosphoramidite monomers 4.3a-
c and phosphoramidite capping agent 4.25. 
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To demonstrate the capability of the dM-Dmoc ODN synthesis technology for 
incorporating electrophilic groups, we also needed phosphoramidite monomers 4.26a-c, 
which contained the sensitive functionalities ester, α-chloroacetamide and thioester, 
respectively (Figure 2). The synthesis of 4.26b-c has been reported [40]. Scheme 3 shows 
the synthesis of 4.26a. The required 1,2-diol 4.28 was simply prepared from the 
commercially available 4.27 by esterification in ethanol. Cyclization or oligomerization of 
4.27 was not an issue for the transformation. The primary alcohol of 4.28 was selectively 
tritylated with DMTrCl to give 4.29, which was phosphitylated with 4.13 in the presence 
of 4.14 to give 4.26a. 
 
 
 
 
Figure 4.2. Structure of phosphoramidites containing electrophilic groups. 
 
 
 
 
 
 
Scheme 4.3. Synthesis of ester-containing phosphoramidite 4.26a. 
 
 
87 
With the required phosphoramidite monomers (4.3a-c) and linker (4.4) in hand, we decided 
to identify suitable conditions for ODN synthesis, deprotection and cleavage under non-
nucleophilic conditions by synthesizing the unmodified ODNs 4.30a-b (Figure 4.3). The 
syntheses were conducted at a scale of 0.52 µmol on a MerMade 6 DNA/RNA synthesizer. 
The dT-Dmoc-CPG (4.4) was used as the solid support. Detritylation was carried out under 
standard conditions suggested by the synthesizer manufacturer for 1 µmol synthesis. The 
0.1 M acetonitrile solutions of phosphoramidite monomers 4.3a-c and the commercially 
available 5'-DMTr β-cyanoethyl dT phosphoramidite were used for incorporating dA, dC, 
dG and dT nucleotides, respectively. The coupling conditions were standard except that in 
some cases, coupling was increased from two to three times. Capping failure sequences 
was achieved using the phosphoramidite 4.25 with 5-(ethylthio)-1H-tetrazole as activator 
instead of the typically used acetic anhydride. Oxidation was performed under standard 
conditions. The last nucleotide at the 5'-end of ODN was incorporated with a 5'-trityl 
nucleoside phosphoramidite instead of a 5'-DMTr counterpart. At the end of the synthesis, 
the 5'-trityl group was not removed. More details about the synthesis are given in the 
Experimental Section. For cleavage and deprotection under non-nucleophilic conditions, 
the ODN on CPG, which should appear as 4.31 (Scheme 4.4) with a 5'-trityl tag, was treated 
with a DBU solution in acetonitrile at room temperature briefly. This removed the β-
cyanoethyl phosphate protecting groups to give 4.32. HPLC analysis of the DBU solution 
did not found any ODN that was cleaved prematurely – an observation consistent with the 
slow rate of cleavage of succinyl-anchored ODNs from solid support under similar 
conditions. 50 The dithioketal groups in the dM-Dmoc and Dmoc functions of 4.32 were 
then oxidized with a solution of sodium periodate at room temperature to give 4.33. The 
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5'-trityl tag survived the conditions. It should be pointed out that some sulfoxides might be 
further oxidized to sulfones, which should not affect the overall results of the deprotection 
and cleavage procedure. Removal of the oxidized dM-Dmoc protection groups and 
cleavage of the oxidized Dmoc linker were achieved with a solution of the weak non-
nucleophilic base potassium carbonate at pH 8 at room temperature giving the fully 
deprotected 5'-trityl-tagged ODN 4.30 (Scheme 4.4). Purification of the ODN 4.30a was 
achieved in two steps – trityl-on RP HPLC followed by trityl-off RP HPLC. For trityl-on 
HPLC (profile a, Figure 4.4), the desired full-length 5'-trityl-tagged ODN appeared at 36-
39 minutes and was well separated from other peaks. This peak was collected, and analyzed 
with RP HPLC (profile b). The purified 5'-trityl-tagged ODN was detritylated with 80% 
acetic acid. Even though it was reported that removal of trityl groups from a primary 
alcohol required two days at room temperature with 80% acetic acid, 51 we found that our 
detritylation could reach completion or in some cases close to completion in three hours. 
After the acid was evaporated, the de-tritylated ODN was purified again with RP HPLC 
(profile c). The major peak at around 20 minutes was collected, the ODN from which 
showed a single sharp peak when analyzed with RP HPLC (profile d). The purified de-
tritylated ODN was further analyzed with polyacrylamide gel electrophoresis (PAGE), a 
single band was observed (Lane 1, Figure 4.5). The HPLC purified ODN was also analyzed 
with MALDI-TOF MS, molecular mass corresponding to correct ODN structure was found 
(Figure 4.6). The unmodified ODN 4.30b were synthesized, purified and analyzed under 
the same conditions. Its HPLC profiles and MS are in the Supporting Information, and 
PAGE image is in Figure 4.5. All the analytical data indicate that the ODNs were pure and 
had correct identity. 
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Figure 4.3. ODN sequences 4.30a-e. Their 5'-tritylated versions are labeled as 4.30a-tr, 
4.30b-tr, 4.30c-tr, 4.30d-tr, and 4.30e-tr, respectively. 
 
In the RP HPLC profiles of the crude 5'-trityl-tagged ODNs such as that for 4.30a-
tr (profile a, Figure 4.4), besides failure sequences at around 20 minutes, there were 
multiple peaks after 40 minutes. We believe that those peaks were from branched ODNs 
generated from the premature deprotection of dM-Dmoc groups during ODN synthesis. 
The dM-Dmoc protections, which contained a tertiary butyl carbamate moiety, were not 
completely stable under the acidic conditions needed for de-tritylation in each synthetic 
cycle. Once the protection was lost, in the coupling step, incoming phosphoramidites would 
react with the free amino groups, and branched ODNs would be produced. Fortunately, 
these branched ODNs had two or more 5'-trityl groups, and therefore were significantly 
more hydrophobic than the desired ODN. During RP HPLC, they were eluted significantly 
later than the desired ODN and could be easily removed. We believe that the branching 
problem was not caused by premature oxidation of the dM-Dmoc groups by iodine in the 
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oxidation step in ODN synthesis because the problem did not exist when Dmoc was used 
for ODN synthesis. 41 In addition, we also subjected 1,3-dithiane to the iodine oxidation 
conditions for over 24 hours, no oxidation could be detected. Before using 4.25 for capping 
and trityl group for 5'-tagging in ODN synthesis using 4.3a-c and 4.4, we tried to synthesize 
ODNs under standard conditions using acetic anhydride for capping and without tagging 
the 5'-end of ODNs. RP HPLC analyses showed that the peaks of the desired ODNs and 
branched sequences were very close and, in some cases, even overlapped, which made 
HPLC purification of the products difficult. A typical RP HPLC profile of ODNs 
synthesized in that manner is given in the Supporting Information. We therefore tried to 
keep the 5'-DMTr group at the end of solid phase synthesis to assist HPLC purification 
hypothesizing that the desired ODN with one DMTr group would be easy to be separated 
from any branched sequences that had two or more DMTr groups. This was indeed the 
case. A RP HPLC profile is given in the Supporting Information. However, the sodium 
periodate oxidation conditions used for ODN cleavage and deprotection were slightly 
acidic, and in most cases, we were not able to keep the DMTr groups. This problem made 
the method unreliable. We also tried to tag the ODN with the hydrophobic t-
butyldiphenylsilyl (TBDPS) group. In RP HPLC profiles, the desired TBDPS-tagged full-
length sequence was also separated very well from the branched sequences (Supporting 
Information). However, at this time we could not identify a mild condition to remove the 
tag after purification of the ODN. These experiments directed us to the use of the trityl tag 
to assist ODN purification as described above. The reason for us to use 4.25 instead of 
acetic anhydride for capping was based on two considerations. One was that if a branched 
sequence failed to react at one or more sites during coupling, capping with a hydrophobic 
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agent would still make the branched sequence more hydrophobic than the desired full-
length sequence. Another consideration was that with acetic anhydride for capping, 
chances existed for replacing the dM-Dmoc groups with acetyl group during capping due 
to the presence of acids such as pyridinium acetate and large excess of acetic anhydride. 
Once the capping exchange occurred, the ODN molecule with an acetyl group would not 
be useful because the acetyl group would not be deprotectable under the mild deprotection 
conditions. Using 4.25 for capping, such capping exchange would not occur. 
Scheme 4.4. ODN deprotection and cleavage under non-nucleophilic conditions. 
 
After identifying suitable conditions for the synthesis of unmodified ODNs under 
non-nucleophilic conditions using the dM-Dmoc technology, studying the feasibility of the 
technology for the synthesis of modified ODNs containing ester, α-chloroacetamide and 
thioester groups was pursued. These groups are sensitive to nucleophiles and cannot 
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survive the commonly used concentrated ammonium hydroxide deprotection and cleavage 
conditions. We have demonstrated that the so called UltraMild deprotection and cleavage 
conditions involving potassium carbonate in anhydrous methanol are incompatible with α-
chloroacetamide and thioester. 40 These findings are easily understandable because the 
species responsible for the cleavage and deprotection under UltraMild conditions is 
potassium methoxide, which is a strong nucleophile. The ODNs 4.30c-e were chosen as 
the targets for the current study. The synthesis, deprotection and cleavage conditions were 
the same as those for the unmodified ODNs. The electrophilic groups were introduced with 
4.26a-c, respectively. In all cases, we placed the groups in the middle of the sequences, 
which is significantly more challenging than placing them at the 5'-end. The fully 
deprotected crude ODNs 4.30c-e were purified and analyzed as described for 4.30a. The 
HPLC profiles of crude and pure 4.30c are given in Figure 4.4. Its PAGE and MALDI-
TOF MS images are in Figures 4.5 and 4.6, respectively. All analytical data for 4.30d-e are 
given in the Supporting Information. It is noted that aminolysis and hydrolysis of the 
sensitive groups in the ODNs, which were found to be a problem previously, 41 were 
successfully avoided by using the dM-Dmoc protection strategy. For all the five ODNs 
(4.30a-e), their OD260 after HPLC purification were determined (Supporting Information). 
They ranged from 2.32 to 6.68 for the 0.52 µmol syntheses. To have a direct comparison 
with standard ODN synthesis technology, we also synthesized 4.30a using commercial 
phosphoramidites and 0.52 µmol 4.4 (Supporting Information). After purification with RP 
HPLC, the OD of 4.30a was determined to be 8.30. With these data, we were able to 
conclude that the dM-Dmoc phosphoramidites had similar coupling efficiency as 
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commercial phosphoramidites and the overall yields of ODNs from the dM-Dmoc 
technology were at the same level of those from standard technologies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. RP HPLC profiles of (a) crude 4.30a-tr, (b) pure 4.30a-tr, (c) crude 4.30a, 
(d) pure 4.30a, (e) crude 4.30c-tr, (f) pure 4.30c-tr, (g) crude 4.30c, (h) pure 4.30c. In 
profiles (a) and (e), the well-separated major peak before 40 minutes is the trityl-tagged 
full-length ODN. The peaks after 40 minutes are branched sequences with two or more 
trityl tags. 
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Figure 4.5. PAGE analyses of ODNs 4.30a-e. Lanes 1-5 are ODNs 4.30a-e, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6. MALDI-TOF MS of (a) ODN 4.30a and (b) 4.30c. 
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The successful synthesis and HPLC purification of the above five ODNs 
demonstrated that dM-Dmoc is a viable choice for amino protection for electrophilic ODN 
synthesis. Compared with using Dmoc for ODN synthesis, the major advantage of using 
dM-Dmoc is that deprotection can be achieved without using any nucleophilic scavengers. 
Using Dmoc, during deprotection after sodium periodate oxidation, large excess aniline is 
needed to induce β-elimination (see Scheme 4.1) and to prevent the side product 4.1 from 
reacting with the deprotected ODN via Michael addition. 40 Aniline is a weak base and 
only mildly nucleophilic. Electrophiles that are compatible with ODNs but reactive toward 
it are rare. However, using large excess of aniline could be a significant drawback. For 
example, many electrophiles could be considered unreactive to it, but in the presence of 
large excess of it, problems might arise. In addition, its boiling point is high, alternative 
techniques other than simple evaporation has to be used for its removal. In order to 
accomplish our goal of developing a universally useful technology for electrophilic ODN 
synthesis, the dM-Dmoc technology is a logical extension of our previous effort. 40 Using 
dM-Dmoc, the side product of deprotection is 4.2. We believe that 4.2 could not react with 
the nucleophiles on ODNs including hydroxyl and amino groups. Even the reaction took 
place, a hindered four-substituted carbon centre would be formed. Because the Michael 
addition reaction is reversible, the adducts would easily fall apart to give back un-modified 
ODNs. Indeed, due to the use of dM-Dmoc, we were able to induce β-elimination with 
potassium carbonate in the absence of any scavenger under mild conditions. Besides the 
advantage of avoiding the use of excess aniline as a scavenger, in the new studies, we also 
found that the acetic acid used in our previous studies for sodium periodate oxidation could 
be omitted. In that report 40 for oxidation of the dithioketals in Dmoc, an acidic solution of 
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sodium periodate adjusted to pH 2 with acetic acid was used. Under those conditions, β-
elimination did not occur and the ODNs remained on the solid support during oxidation. 
This greatly facilitated the removal of excess sodium periodate and its reduced salts 
because they could be easily washed away with water. Otherwise, more expensive means 
such as size exclusion chromatography had to be used. In our new studies, we tested to 
perform the oxidation in the absence of acetic acid. We found that the pH of 0.4 M sodium 
periodate solution was around 4, and this solution did not cause premature β-elimination 
during oxidation. Therefore, the ODNs remained on the solid support under this 
significantly less acidic conditions. Because ODNs are inherently unstable under acetic 
conditions, avoiding the use of acetic acid and performing the cleavage and deprotection 
at nearly neutral pH could make the technology more useful. In addition, the scope of 
sensitive functionalities to be introduced to ODNs using the technology could be further 
extended. The finding of the stability of the Dmoc function in linker 4.4 after oxidation 
under nearly neutral conditions is also important for considering using the technology for 
oligoribonucleotides (ORNs) synthesis. One potential problem to use the technology for 
ORN synthesis is that during oxidation of the Dmoc and dM-Dmoc functions using sodium 
periodate, if the oxidized Dmoc in the linker were unstable, and the 2' and 3'-OH groups 
were exposed before sodium periodate were removed, the C-C bond between the 2' and 3' 
carbons could be cleaved. With the finding of the relatively high stability of the oxidized 
Dmoc function, we are more confident that the Dmoc associated technologies will be useful 
for ORN synthesis as well. 
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4.3 Conclusion 
 
In summary, we have extended the Dmoc-based electrophilic ODN synthesis 
technology to a new level, at which dM-Dmoc is used for protecting exo-amino groups of 
nucleobases. With this advancement, the previously used large excess aniline for 
scavenging the Michael acceptor side product during cleavage and deprotection was no 
longer needed. This makes the technology more convenient to use and could extend its 
scope on incorporating different sensitive functionalities into ODNs. In addition, we found 
that the sodium periodate oxidation step for cleavage and deprotection could be performed 
in the absence of acetic acid at nearly neutral conditions instead of previously used acidic 
conditions. Because ODNs and many functionalities are sensitive to acid, the significantly 
less acidic conditions will eliminate concerns of ODN damage and increase the scope of 
functionalities capable to be incorporated into ODNs. Using the technology, five ODNs 
including three modified ones containing the sensitive groups – ester, α-chloroamide and 
thioester – were successfully synthesized. We expect that the technology will become a 
useful tool for the synthesis of sensitive ODN analogs. 
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4.4 Experimental Section 
 
General information: 
All reactions were performed in oven-dried glassware under argon using standard 
Schlenk techniques. Reagents and solvents available from commercial sources were used 
as received unless otherwise noted. Lcaa-CPG (pore size 497 Å) was purchased from Prime 
Synthesis, Inc. Polyacrylamide desalting column (5K MWCO, 10 mL) was purchased from 
Thermo Scientific. THF and CH2Cl2 was dried using an Innovative Technology Pure-
Solv™ system. Pyridine, diisopropylamine and acetone were distilled over CaH2 under 
nitrogen. Thin layer chromatography (TLC) was performed using Sigma-Aldrich TLC 
plates, silica gel 60F-254 over glass support, 250 μm thickness. Flash column 
chromatography was performed using SiliCycle silica gel, particle size 40-63 μm. 1H, 13C 
and 31P NMR spectra were measured on a Varian UNITY INOVA spectrometer at 400, 
100 and 162 MHz, respectively; chemical shifts (δ) were reported in reference to solvent 
peaks (residue CHCl3 at δ 7.24 ppm for 1H and CDCl3 at δ 77.00 ppm for 13C) and to H3PO4 
(δ 0.00 ppm for 31P). HRMS was obtained on a Thermo HR-Orbitrap Elite Mass 
Spectrometer. LRMS was obtained on a Thermo Finnigan LCQ Advantage Ion Trap Mass 
Spectrometer. MALDI-TOF MS were obtained on Bruker’s microflex™ LRF MALDI-
TOF System. ODNs were synthesized on a MerMade 6 solid phase synthesizer. RP HPLC 
was performed on a JASCO LC-2000Plus System: pump, PU-2089Plus Quaternary 
Gradient; detector UV-2075Plus. A C-18 reversed phase analytical column (5 μm diameter, 
100 Å, 250 × 3.20 mm) was used. Solvent A: 0.1 M triethylammonium acetate, 5% 
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acetonitrile. Solvent B: 90% acetonitrile. All profiles were generated by detecting 
absorbance at 260 nm using the linear gradient solvent system: solvent B (0%-45%) in 
solvent A over 60 min followed by solvent B (45%-100%) in solvent A over 20 min at a 
flow rate of 1.0 mL/min. PAGE of ODNs was run in a gel slide casted with a stock solution 
prepared using the recipe – 62.5 mL 40% acrylamide and bis-acrylamide (19:1), 52.55 g 
urea, 6.25 mL 10 × TBE (tris/borate/EDTA) buffer, and suitable amount of DI water for a 
total 100 mL solution. The gel slide was casted with 7 mL of the stock solution, 70 µL 10% 
(NH4)2S2O4, and 7 µL TMEDA (tetramethylethylenediamine). Electrophoresis was run in 
10 × TBE buffer at 200 V by pre-run (without sample) for 30 min followed by actual run 
(with sample) for 90 min. The gel was stained with SYBR® Gold, and images were 
obtained with a BioRad Gel Doc™ XR+ Gel Documentation System. 
Compound 4.7: 1 
To a solution of 1,3-dithiane (4.6, 5.0 g, 41.6 mmol) in dry THF (100 mL) was slowly 
added nBuLi (2.5 M in pentane, 15.7 mL, 41.6 mmol) under argon at -78 °C. After stirring 
for 30 min, freshly distilled acetone (3.0 mL, 41.6 mmol) was added dropwise at -78 °C. 
The reaction was allowed to proceed for 8 h while warming to rt, and then quenched with 
saturated NH4Cl (75 mL). The mixture was extracted with EtOAc (50 mL × 2). The extracts 
were combined and dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
was purified with flash column chromatography (SiO2, 4:1 hexanes/EtOAc) to afford 4.7 
as a white solid (6.24 g, 84%). 1 
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Compound 4.5: 1 
To a solution of 4.7 (6.4 g, 36 mmol) and pyridine (2.9 mL, 54 mmol) in DCM (100 mL) 
was added p-nitrophenyl chloroformate (4.8, 7.2 g, 36 mmol) at rt under argon. After 
stirring at rt for 8 h, the contents were poured into a separatory funnel and partitioned 
between EtOAc (40 mL) and H2O (80 mL). The aqueous layer was extracted with DCM 
(50 mL × 2). The combined organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. Flash column chromatography (SiO2, 9:1 hexanes/EtOAc) gave 4.5 as a 
white solid (10.0 g, 81%). 1 
Compound 4.10: 
To a solution of diisopropyl amine (1.2 mL, 8.5 mmol) in THF at -78 °C was added nBuLi 
(2.5 M in pentane, 3.2 mL, 8.1 mmol) and stirred for 30 min. The freshly prepared LDA 
solution was added via a cannula to a solution of 4.9 (1.9 g, 4.05 mmol) in THF (50 mL) 
at -78 °C. After stirring for 30 min, compound 4.5 was added as a solid under positive 
nitrogen pressure at -78 °C. The mixture was stirred for 8 h while warming to rt. The 
contents were poured into a separatory funnel and partitioned between EtOAc (40 mL) and 
H2O (40 mL). The aqueous layer was extracted with EtOAc (30 mL × 2). The combined 
organic layer was dried over anhydrous Na2SO4, filtered and concentrated. Flash column 
chromatography (SiO2, 1:1 hexanes/EtOAc) gave 4.10 as a white foam (2.33 g, 86%): Rf = 
0.6 (1:2 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3): δ 0.89-1.02 (m, 28H), 1.57 (s, 6H), 
1.71-1.78 (m, 1H), 2.00-2.04 (m, 1H), 2.23-2.28 (m, 1H), 2.46-2.53 (m, 1H), 2.76-2.86 (m, 
4H), 3.73 (d, J = 8.5 Hz, 1H), 3.93-3.97 (m, 1H), 4.09-4.12 (m, 1H), 4.27-4.33 (m, 1H), 
4.92 (s, 1H), 5.98 (d, J = 6.5 Hz, 1H), 7.05 (d, J = 7.4 Hz, 1H), 8.10 (d, J = 7.4 Hz, 1H); 
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13C NMR (100 MHz, CDCl3): δ 12.5, 13.12, 13.16, 13.6, 16.9, 17.10, 17.12, 17.2, 17.5, 
17.64, 17.67, 24.7, 25.9, 31.0, 39.9, 56.8, 60.0, 66.7, 85.2, 85.3, 85.7, 94.5, 143.9, 150.8, 
154.9, 162.6; HRMS (ESI): m/z calcd for C29H52N3O7S2Si2 [M + H]
+ 674.2785, found 
674.2783. 
Compound 4.11: 
To the THF (10 mL) solution of 4.10 (800 mg, 1.19 mmol) at rt was added TBAF (1 M in 
THF, 3.0 mL, 3.0 mmol). The mixture was stirred for 1 h. THF was evaporated and the 
residue was loaded directly on a column. Flash column chromatography (SiO2, 9.5:0.5 
EtOAc/MeOH) gave 4.11 as a white foam (0.507 g, 99%): Rf  = 0.3 (9.5:0.5 
EtOAc/MeOH); 1H NMR (400 MHz, CD3OD): δ 1.60 (s, 6H), 1.70-1.77 (m, 1H), 2.04-
2.10 (m, 1H), 2.12-2.18 (m, 1H), 2.43-2.49 (m, 1H), 2.82-2.94 (m, 4H), 3.71 (dd, J = 12.1, 
3.8 Hz, 1H), 3.81 (dd, J = 12.1, 3.2 Hz, 1H), 3.96-3.99 (m, 1H), 4.33-4.37 (m, 1H), 4.81 
(s, 2H), 5.07 (s, 1H), 6.19 (t, J = 6.2 Hz, 1H), 7.22 (d, J = 7.5 Hz, 1H), 8.40 (d, J = 7.5 Hz, 
1H); 13C NMR (100 MHz, CD3OD): δ 24.0, 26.0, 30.7, 41.3, 56.8, 61.3, 70.4, 84.5, 87.3, 
88.2, 95.5, 144.4, 151.6, 156.4, 163.5; HRMS (ESI): m/z calcd for C17H24N3O6S2 [M - H]
- 
430.1107, found 430.1112. 
Compound 4.12: 
To a solution of 4.11 (513 mg, 1.19 mmol) in pyridine (10 mL) at 0 °C was added DMTrCl 
(440 mg, 1.31 mmol) under positive nitrogen pressure. The mixture was stirred for 8 h 
while warming to rt. The volume of the mixture was reduced to about 2 mL under vacuum 
from an oil pump (small amount of pyridine was intentionally left to ensure basicity of the 
residue, which could help to avoid losing DMTr from product). The residue was partitioned 
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between 5 % Na2CO3 (30 mL) and EtOAc (30 mL). The aqueous layer was extracted with 
EtOAc (15 mL × 2). The combined organic layer was dried over anhydrous Na2SO4, 
filtered and concentrated to dryness. Flash column chromatography (SiO2, 9.5:0.5:0.5 
EtOAc/MeOH/Et3N) gave 4.12 as a white foam (523 mg, 60%): Rf  = 0.5 (9.5:0.5:0.5 
EtOAc/MeOH/Et3N); 
1H NMR (400 MHz, CDCl3): δ 1.57 (s, 6H), 1.68-1.79 (m, 1H), 1.99-
2.03 (m, 1H), 2.14-2.21 (m, 1H), 2.67-2.73 (m, 1H), 2.80-2.83 (m, 4H), 3.31-3.34 (m, 1H), 
3.41-3.44 (m, 1H), 3.73 (s, 6H), 4.15 (d, J = 3.3 Hz,1H), 4.49 (d, J = 4.3 Hz, 1H), 4.93 (s, 
1H), 6.2 (t, J = 5.2 Hz, 1H), 6.79 (d, J = 8.3 Hz, 4H), 6.90 (d, J = 7.3 Hz, 1H), 7.16 (t, J = 
7.0 Hz, 1H), 7.25 (d, J = 8.6 Hz, 4H), 7.36 (d, J = 7.6 Hz, 2H), 8.03 (bs, 1H), 8.23 (d, J = 
7.4 Hz); 13C NMR (100 MHz, CDCl3): δ 24.8, 26.0, 31.1, 42.3, 55.4, 56.9, 62.9, 70.6, 85.1, 
86.7, 86.9, 87.4, 95.2, 113.5, 127.2, 128.2, 128.4, 130.1, 130.2, 135.7, 135.9, 144.4, 150.9, 
155.6, 158.7, 162.6; HRMS (ESI): m/z calcd for C38H44N3O8S2 [M + H]
+ 734.2569, found 
734.2565. 
Compound 4.3a: 
To a solution of 4.12 (500 mg, 0.682 mmol) and diisopropylammonium tetrazolide (4.14, 
175 mg, 1.02 mmol) in DCM (10 mL) at rt was added 2-cyanoethyl N,N,N',N'-
tetraisopropylphosphorodiamidite (13, 325 µL, 1.02 mmol). After stirring at rt for 2 h, the 
reaction mixture was concentrated and loaded directly on a column. Flash column 
chromatography (SiO2, 4:1:0.25 EtOAc/hexanes/Et3N) gave 4.3a as a white foam (580 mg, 
91%): Mixture of two diastereoisomers; Rf = 0.3 and 0.4 (EtOAc); 
1H NMR (400 MHz, 
CDCl3): δ 1.03 (d, J = 6.7 Hz, 2H), 1.11-1.20 (m, 12H), 1.23-1.30 (m, 3H), 1.61 (s, 6H), 
2.02-2.08 (m, 1H), 1.73-1.83 (m, 1H), 2.02-2.08 (m, 1H), 2.18-2.29 (m, 2H), 2.40 (t, J = 
103 
6.4 Hz, 1H), 2.57 (t, J = 6.4 Hz, 1H), 2.65-2.75 (m, 2H), 2.81-2.89 (m, 4H), 3.29-3.36 (m, 
1H), 3.45-3.60 (m, 5H), 3.78 (d, J = 3.5 Hz, 6H), 4.14-4.18 (m, 1H), 4.53-4.62 (m, 1H), 
4.92 (s, 1H), 6.20-6.26 (m 1H), 6.82 (t, J = 7.9 Hz, 5H), 7.26 (t, J = 7.7 Hz, 6H), 7.37 (t, J 
= 7.2 Hz, 2H), 8.17 (d, J = 8.0 Hz, 1H), 8.26 (d, J = 7.7 Hz, 1H); 13C NMR (100 MHz, 
CDCl3): δ 20.3, 24.7, 26.0, 31.0, 41.0, 41.4, 43.4, 55.4, 56.8, 58.5, 62.1, 62.5, 85.2, 85.7, 
87.0, 94.8, 113.4, 117.7, 128.1, 128.4, 128.5, 130.21, 130.26, 130.3, 135.6, 144.2, 150.8, 
155.0, 158.8, 162.4; 31P NMR (162 MHz, CDCl3): δ 149.7, 150.4; HRMS (ESI): m/z calcd 
for C47H61N5O9PS2 [M + H]
+ 934.3648, found 934.3652. 
Compound 4.16: 
The procedure for synthesizing 4.10 was used. After flash column chromatography (SiO2, 
1:2 EtOAc/hexanes) 4.16 was afforded as a white foam in 53% yield: Rf = 0.5 (1:1 
EtOAc/hexanes); 1H NMR (400 MHz, CDCl3): δ 0.97-1.05 (m, 28H), 1.61 (d, J = 7.5 Hz, 
6H), 1.72-1.78 (m, 1H), 2.01-2.07 (m, 1H), 2.60-2.68 (m, 2H), 2.79-2.90 (m, 4H), 3.85-
3.88 (m, 1H), 4.01 (t, J = 4.0 Hz, 2H), 4.91 (q, J = 7.6 Hz, 1H), 5.14 (s, 1H), 6.28-6.30 (m, 
1H), 8.19 (s, 1H), 8.68 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 12.7, 13.0, 13.2, 13.5, 17.0, 
17.1, 17.2, 17.3, 17.5, 17.5, 17.6, 17.6, 40.2, 56.9, 61.8, 69.8, 83.6, 84.7, 85.4,122.5, 141.3, 
149.4, 149.9, 150.2, 152.9; HRMS (ESI): m/z calcd for C30H52N5O6S2Si2 [M + H]
+ 
698.2897, found 698.2896. 
Compound 4.17: 
The procedure for synthesizing 4.11 was used. After flash column chromatography (SiO2, 
9:1 EtOAc/MeOH) 4.17 was afforded as a white foam in 71% yield: Rf = 0.3 (9:1 
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EtOAc/MeOH); 1H NMR (400 MHz, CDCl3): δ 1.67 (s, 6H), 1.69-1.83 (m, 1H), 2.03-2.09 
(m, 1H), 2.34-2.37 (m, 2H), 2.84-2.90 (m, 4H), 2.93-3.08 (m, 1H), 3.81-3.97 (m, 2H), 4.24 
(s, 1H), 4.82 (s, 1H), 5.17 (s, 1H), 5.84-5.87 (m, 1H), 6.36-6.40 (m, 1H), 8.02 (s, 1H), 8.42 
(s, 1H), 8.73 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 24.9, 26.1, 31.2, 41.1, 57.1, 63.5, 
73.3, 85.0, 87.8, 89.7, 123.4, 142.4, 149.2, 150.1, 150.6, 152.5; HRMS (ESI): m/z calcd for 
C18H26N5O5S2 [M + H]
+ 456.1375, found 456.1381. 
Compound 4.18: 
The procedure for synthesizing 4.12 was used. After flash column chromatography (SiO2, 
9:0.5:0.5 EtOAc/MeOH/Et3N) 4.18 was afforded as a white foam in 63% yield: Rf = 0.4 
(9.5:0.5 EtOAc/MeOH); 1H NMR (400 MHz, CDCl3): δ 1.60 (s, 6H), 1.67-1.75 (m, 1H), 
1.95-2.04 (m, 1H), 2.49-2.57 (m, 1H), 2.73-2.86 (m, 5H), 3.34 (d, J = 3.8 Hz, 2H), 3.67 (s, 
6H), 4.16-4.21 (m, 1H), 4.66-4.70 (m, 1H), 5.10 (s, 1H), 5.21 (s, 1H), 6.44 (t, J = 6.3 Hz, 
1H), 6.69 (d, J = 8.7 Hz, 4H), 7.07-7.21 (m, 7H), 7.30 (d, J = 8.0 Hz, 2H), 8.08 (s, 1H), 
8.63 (s, 1H), 8.99 (bs, 1H); 13C NMR (100 MHz, CDCl3): δ 24.9, 26.0, 31.1, 40.6, 55.4, 
57.0, 63.8, 72.3, 84.6, 84.9, 86.7, 113.3, 122.1, 127.1, 128.0, 128.2, 130.1, 141.3, 144.6, 
149.5, 149.9, 150.7, 152.9, 158.6; HRMS (ESI): m/z calcd for C39H44N5O7S2 [M + H]
+
 
758.2682, found 758.2685. 
Compound 4.3b: 
The procedure for synthesizing 4.3a was used. After flash column chromatography (SiO2, 
2:1:0.15 EtOAc/hexanes/Et3N) 4.3b was afforded as a white foam in 77% yield: Mixture 
of two diastereoisomers; Rf = 0.3 and 0.4 (2:1 EtOAc/hexanes); 
1H NMR (400 MHz, 
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CDCl3): δ 1.15-1.23 (m, 12H), 1.63 (s, 6H), 1.74-1.80 (m, 1H), 2.02-2.07 (m, 1H), 2.42 (t, 
J = 6.4 Hz, 1H), 2.57 (t, J = 6.4 Hz, 1H), 2.79-2.91 (m, 4H), 3.28-3.33 (m, 1H), 3.38-3.44 
(m, 2H), 3.54-3.60 (m, 2H), 3.75 (s, 6H), 3.79-3.87 (m, 1H), 4.08-4.14 (m, 1H), 4.24-4.29 
(m, 1H), 4.71-4.77 (m, 1H), 5.14 (s, 1H), 6.40-6.45 (m, 1H), 6.72-6.75 (m, 4H), 7.14-7.25 
(m, 7H), 7.33-7.35 (m, 2H), 8.11 (d, J = 9.5 Hz, 1H), 8.38 (bs, 1H), 8.65 (s, 1H); 13C NMR 
(100 MHz, CDCl3): δ 20.1, 20.7, 22.5, 23.4, 24.8, 25.0, 26.2, 31.3, 39.7, 45.3, 45.5, 45.8, 
55.4, 57.0, 58.5, 58.7, 63.6, 73.6, 74.4, 84.7, 84.7, 84.9, 86.0, 86.2, 86.7, 113.2, 117.6, 
122.4, 127.0, 127.9, 128.2, 130.1, 135.7, 141.3, 144.5, 149.2, 149.7, 150.8, 152.8, 158.6; 
31P NMR (162 MHz, CDCl3): δ 149.7, 149.9; HRMS (ESI): m/z calcd for C48H60N7O8PS2H 
[M + H]+ 958.3760, found 958.3769. 
Compound 4.21: 
The amide functionality in 4.19 was protected with a TBS group by reacting with TBSCl 
(3 equiv.) in the presence of imidazole (6 equiv.) in DCM at rt for 8 h. 2 The crude 
intermediate 4.20 was partitioned between DCM and NaH2PO4/Na2HPO4 buffer (pH 7) 
and further washed with the buffer two times. The organic phase was dried over Na2SO4, 
filtered and concentrated to dryness. After the crude intermediate was dried under high 
vacuum over Drierite, 4.20 was converted to 4.21 following the procedure for synthesizing 
4.10. The TBS group probably fell off during partition between EtOAc and saturated 
NH4Cl. After flash column chromatography (SiO2, 1:1 EtOAc/hexanes) 4.21 was afforded 
as a brown foam in 55% yield: Rf = 0.3 (1:1 EtOAc/hexanes); 
1H NMR (400 MHz, CDCl3): 
δ 0.96-1.08 (m, 28H), 1.63 (s, 6H), 1.77-1.85 (m, 1H), 2.08-2.15 (m, 1H), 2.52-2.55 (m, 
2H), 2.85-2.92 (m, 4H), 3.81-3.85 (m, 1H), 3.94-4.04 (m, 2H), 4.71 (q, J = 7.4 Hz, 1H), 
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4.96 (s, 1H), 6.08 (t, J = 5.2 Hz, 1H), 7.82 (s, 1H); 13C NMR (100 MHz, CDCl3): δ 12.8, 
13.3, 13.4, 13.7, 17.20, 17.28, 17.3, 17.45, 17.47, 17.5, 17.6, 17.7, 17.8, 24.9, 26.0, 31.4, 
40.3, 57.0, 62.0, 70.2, 82.8, 85.4, 86.9, 121.5, 136.7, 146.7, 147.3, 151.8, 155.6; HRMS 
(ESI): m/z calcd for C30H52N5O7S2Si2 [M + H]
+ 714.2847, found 714.2842.   
Compound 4.22: 
The pro-cedure for synthesizing 4.11 was used. After flash column chromatography (SiO2, 
4:1 EtOAc/MeOH) 4.22 was afforded as a brown foam in 80% yield: Rf = 0.2 (9:1 
EtOAc/MeOH); 1H NMR (400 MHz, CD3OD): δ 1.79 (s, 6H), 1.70-1.79 (m, 1H), 2.00-
2.10 (m, 1H), 2.39-2.44 (m, 1H), 2.60-2.70 (m, 1H), 2.85-2.92 (m, 4H), 3.22 (s, 1H), 3.70-
3.76 (m, 2H), 3.92-4.05 (m, 2H), 4.50-4.54 (m, 1H), 5.16 (s, 1H), 8.20 (s, 1H); 13C NMR 
(100 MHz, CD3OD): δ 23.6, 30.6, 40.4, 56.7, 61.8, 71.1, 84.3, 85.8, 88.0, 119.6, 138.2, 
148.0, 153.7, 156.3; HRMS (ESI): m/z calcd for C18H26N5O6S2 [M + H]
+ 472.1324, found 
472.1326. 
Compound 4.23: 
The procedure for synthesizing 4.12 was used. After flash column chromatography (SiO2, 
9:0.5:0.5 EtOAc/MeOH/Et3N) 4.23 was afforded as a brown foam in 46% yield: Rf = 0.4 
(9.5:0.5 EtOAc/MeOH); 1H NMR (400 MHz, CDCl3): δ 1.58 (s, 6H), 1.68-1.77 (m, 1H), 
1.97-2.03 (m, 1H), 2.50-2.60 (m, 2H), 2.77-2.85 (m, 4H), 3.25-3.29 (m, 2H), 3.67 (s, 6H), 
4.14-4.22 (m, 1H), 4.69-4.76 (m, 1H), 4.93 (s, 1H), 6.23 (t, J = 6.2 Hz, 1H), 6.69 (d, J = 
8.7 Hz, 4H), 7.07-7.13 (m, 2H), 7.21 (d, J = 8.6 Hz, 4H), 7.31 (d, J = 7.3 Hz, 2H), 7.75 (s, 
1H); 13C NMR (100 MHz, CDCl3): δ 24.7, 25.9, 31.1, 40.6, 55.3, 60.6, 64.4, 72.0, 84.6, 
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86.5, 86.7, 113.2, 120.8, 127.9, 128.3, 130.1, 135.9, 137.7, 144.7, 147.1, 148.6, 152.7, 
155.9, 158.6; HRMS (ESI): m/z calcd for C39H44N5O8S2 [M + H]
+ 774.2631, found 
774.2629.  
Compound 4.3c: 
The procedure for synthesizing 4.3a was used. After flash column chromatography (SiO2, 
9.5:0.5 EtOAc/Et3N) 4.3c was afforded as a brown foam in 76% yield: Mixture of two 
diastereoisomers; Rf = 0.4 and 0.5 (EtOAc); 
1HNMR (400 MHz, CDCl3): δ 1.08-1.25 (m, 
12H), 1.59 (d, J = 7.9 Hz, 6H), 1.74-1.85 (m, 1H), 2.06-2.14 (m, 1H), 2.37-2.47 (m, 2H), 
2.68-2.74 (m, 1H), 2.83-2.91 (m, 4H), 3.26-3.32 (m, 2H), 3.49-3.60 (m, 2H), 3.74 (s, 6H), 
4.08-4.16 (m, 1H), 4.20-4.27 (s, 1H), 4.62-4.71 (m, 1H), 4.97 (s, 1H), 6.11-6.19 (m, 1H), 
6.75 (d, J = 8.4 Hz, 4H), 7.15-7.28 (m, 7H), 7.36-7.38 (m, 2H), 7.72 (s, 1H); 13C NMR 
(100 MHz, CDCl3): δ 20.2, 20.6, 23.10, 23.18, 24.7, 24.8, 26.0, 31.2, 39.7, 43.3, 43.5, 45.5, 
55.4, 56.8, 58.3, 63.9, 74.7, 84.9, 86.5, 86.6, 113.3, 117.6, 121.6, 127.1, 128.0, 130.1, 
135.8, 137.2, 137.5, 144.6, 144.7, 148.3, 152.1, 155.7, 158.7; 31P NMR (162 MHz, CDCl3) 
δ 149.5, 149.7; HRMS (ESI): m/z calcd for C48H61N7O9PS2 [M + H]+ 974.3709, found 
774.3715. 
Compound 4.25: 
The procedure for the synthesis of 4.3a was used. After flash column chromatography 
(SiO2, 4:1:0.25 hexanes/EtOAc/Et3N) 4.25 was afforded as a colorless oil in 88% yield: Rf 
= 0.3 (4:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3) δ 1.14-1.18 (m, 12H), 1.27-1.33 
(m, 6H), 1.55-1.61 (m, 4H), 2.56-2.63 (m, 4H), 3.53-3.63 (m, 4H), 3.74-3.86 (m, 4H), 7.14-
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7.16 (m, 3H), 7.23-7.25 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 20.6 (d, JC-P = 6.74 Hz), 
24.9, 26.2, 29.6 (d, JC-P = 18.72 Hz), 29.5, 29.7, 31.4, 31.5, 31.7, 36.2, 43.2 (d, JC-P = 12.35 
Hz), 58.5 (d, JC-P = 18.95 Hz), 63.9 (d, JC-P = 16.97 Hz), 117.8, 125.7, 128.3, 128.5, 143.0; 
31P NMR (162 MHz, CDCl3) δ 148.5; HRMS (ESI): m/z calcd for C23H40N2O2P [M+H]+ 
407.2827, found 407.2812. 
Compound 4.28: 
A solution of 4.27 (2.0 g, 9.17 mmol) and conc. H2SO4 (1 mL) in ethanol (100 mL) was 
stirred at reflux for 2 h. After cooling to rt, the reaction was quenched with 5% Na2CO3 
(20 mL) and ethanol was evaporated. The remaining material was partitioned between 
EtOAc (100 mL) and 5% Na2CO3 (50 mL). The organic phase was washed with 5% 
Na2CO3 (50 mL × 2), dried over anhydrous Na2SO4, filtered and concentrated. Flash 
column chromatography (SiO2, 1:1 hexanes/EtOAc) gave 4.28 as a colorless oil (1.72  g, 
76%): Rf = 0.2 (1:1 hexanes/EtOAc); 
1H NMR (400 MHz, CD3OD): δ 1.22 (t, J = 7.1 Hz, 
3H), 1.30 (s, 10H), 1.42-1.50 (m, 2H), 1.54-1.60 (m, 2H), 2.27 (t, J = 7.4 Hz, 2H), 3.28 
(bs, 1H), 3.36-3.46 (m, 2H), 3.53 (bs, 1H), 4.08 (q, J = 7.1 Hz, 2H), 4.80 (s, 2H); 13C NMR 
(100 MHz, CD3OD): δ 13.3, 24.8, 25.4, 28.9, 29.1, 29.3, 29.5, 33.2, 33.9, 60.1, 66.2, 72.0, 
174.3; HRMS (ESI): m/z calcd for C13H27O4 [M + H]
+ 247.1909, found 247.1907. 
Compound 4.29: 
The procedure for synthesizing 4.12 was used. After flash column chromatography (SiO2, 
3:2:0.25 hexanes/EtOAc/Et3N) 4.29 was afforded as a yellow oil in 99% yield: Rf = 0.8 
(1:1 hexanes/EtOAc); 1H NMR (400 MHz, CDCl3): δ 1.20-1.28 (m, 10H), 1.35-1.45 (m, 
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2H), 1.53-1.63 (m, 2H), 2.26 (t, J = 7.3 Hz, 2H), 2.47 (bs, 1H), 2.98-3.04 (m, 1H), 3.13-
3.17 (m, 1H), 3.74 (s, 6H), 4.10 (q, J = 7.1 Hz, 2H), 6.81 (d, J = 8.8 Hz, 4H), 7.14-7.19 (m, 
2H), 7.26 (t, J = 7.8 Hz, 2H), 7.31 (d, J = 8.8 Hz, 4H), 7.43 (d, J = 5.8 Hz, 2H); 13C NMR 
(100 MHz, CDCl3): δ 14.4, 25.1, 25.6, 29.31, 29.39, 29.5, 29.7, 33.6, 34.5, 55.3, 60.3, 67.8, 
71.1, 86.2, 113.3, 126.9, 128.0, 128.3, 130.2, 136.3, 145.1, 158.6, 174.0; HRMS (ESI): m/z 
calcd for C34H44O6Na [M + Na]
+ 571.3035, found 571.3031. 
Compound 4.26a: 
The procedure for synthesizing 4.3a was used. After flash column chromatography (SiO2, 
2:1:0.15 hexanes/EtOAc/Et3N) 4.26a was afforded as a colorless oil in 99% yield: Mixture 
of diastereoisomers; Rf = 0.6 and 0.7 (1:1 hexanes/EtOAc); 
1H NMR (400 MHz, CDCl3): 
δ 1.05 (d, J = 6.7 Hz, 4H), 1.14-1.26 (m, 22H), 1.54-1.63 (m, 2H), 2.24-2.29 (m, 2H), 2.35-
2.39 (m, 1H), 2.59 (t, J = 6.5 Hz, 2H), 2.92-2.99 (m, 1H), 3.09-3.18 (m, 2H), 3.50-3.65 (m, 
3H), 3.76 (s, 6H), 3.91-3.99 (m, 1H), 4.11 (q, J = 7.1 Hz, 2H), 6.80 (t, J = 8.7 Hz, 4H), 
7.15-7.20 (m, 2H), 7.23-7.27 (m, 2H), 7.32 (d, J = 8.9 Hz, 4H), 7.45 (d, J = 7.0 Hz, 2H); 
13C NMR (100 MHz, CDCl3): δ 14.4, 20.3, 20.6, 24.6, 24.7, 24.8, 24.9, 25.0, 25.2, 25.3, 
29.3, 29.41, 29.44, 29.5, 29.7, 29.8, 33.6, 33.8, 34.5, 43.1, 43.3, 43.4, 55.3, 58.3, 58.6, 60.3, 
66.2, 66.5, 73.6, 73.7, 74.4, 74.6, 86.0, 86.1, 117.9, 126.81, 126.87, 127.8, 128.4, 128.5, 
130.2, 130.32, 130.36, 136.5, 145.3, 158.6, 174.0 ppm. 31P NMR (162 MHz, CDCl3): δ 
149.1, 149.7; HRMS (ESI): m/z calcd for C43H61N2O7PNa [M + Na]
+ 771.4114, found 
771.4108. 
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Figure A.1. 1H NMR of Compound 2.7 
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Figure A.2. 13C NMR of Compound 2.7 
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Figure A.3. 1H NMR of Compound 2.8 
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Figure A.4. 13C NMR of Compound 2.8 
 
 
 
 
 
 
 
119 
 
Figure A.5. 1H NMR of Compound 2.9 
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Figure A.6. 13C NMR of Compound 2.9 
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Figure A.7. 1HNMR of Compound 2.10 
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Figure A.8. 13CNMR of Compound 2.10 
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Figure A.9. 1HNMR of Compound 2.14 
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Figure A.10. 13CNMR of Compound 2.14 
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Figure A.11. 1HNMR of Compound 2.2 
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Figure A.12. 13CNMR of Compound 2.2 
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Figure A.13. 31PNMR of Compound 2.2 
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Figure A.14. 1HNMR of Compound 2.15 
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Figure A.15. 13CNMR of Compound 2.15 
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Figure A.16. 1HNMR of Compound 2.3 
 
 
 
 
 
 
 
 
 
131 
 
Figure A.17. 13CNMR of Compound 2.3 
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Figure A.18. 31PNMR of Compound 2.3 
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Figure A.19. 1HNMR of Compound 2.19 
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Figure A.20. 13CNMR of Compound 2.19 
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Figure A.21. 1HNMR of Compound 2.4 
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Figure A.22. 13CNMR of Compound 2.4 
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Figure A.23. 31PNMR of Compound 2.4 
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Figure A.24. 1HNMR of Compound 2.27 
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Figure A.25. 13CNMR of Compound 2.27 
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Figure A.26. 1HNMR of Compound 2.23 
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Figure A.27. 31PNMR of Compound 2.23 
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Figure A.28. 31PNMR of Compound 2.28 
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Figure A.29. 13CNMR of Compound 2.28 
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Figure A.30. 1HNMR of Compound 2.24 
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Figure A.31. 31PNMR of Compound 2.24 
 
 
 
 
 
 
 
 
 
146 
Figure A.32. MALDI-TOF-MS of ODN 2.20 
 
 
 
 
 
 
 
 
 
MALDI TOF MS of ODN 2.20 
Calcd for C194H250N61O124P19 
[M]- 6008.02, found 6008.20 
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Figure A.33. MALDI-TOF-MS of ODN 2.21 
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Figure A.34. MALDI-TOF-MS of ODN 2.22 
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Figure A.35. MALDI-TOF-MS of ODN 2.29 
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Figure A.36. MALDI-TOF-MS of ODN 2.30 
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Figure A.37. RP-HPLC profile of crude ODN 2.21 
 
 
 
Figure A.38. RP-HPLC profile of pure ODN 2.21 
 
 
 
 
152 
 
Figure A.39. RP-HPLC profile of crude ODN 2.22 
 
 
 
Figure A.40. RP-HPLC profile of pure ODN 2.22 
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Figure A.41. RP-HPLC profile of pure ODN 2.22 
 
 
Figure A.42. RP-HPLC profile of crude ODN 2.30  
 
 
 
154 
Appendix B. Supporting Information for Chapter 3 
 
 
 
 
Sensitive ODN Synthesis Using Dim for Phosphate Protection 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
155 
 
Figure B.1. 1HNMR of Compound 3.7a 
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Figure B.2. 13CNMR of Compound 3.7a 
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Figure B.3. 31PNMR of Compound 3.7a 
 
 
 
 
 
 
 
 
 
158 
 
Figure B.4. 1HNMR of Compound 3.7b 
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Figure B.5. 13CNMR of Compound 3.7b 
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Figure B.6. 31PNMR of Compound 3.7b 
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Figure B.7. 1HNMR of Compound 3.7c 
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Figure B.8. 13CNMR of Compound 3.7c 
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Figure B.9. 31PNMR of Compound 3.7c 
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Figure B.10. 1HNMR of Compound 3.7d 
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Figure B.11. 13CNMR of Compound 3.7d 
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Figure B.12. 31PNMR of Compound 3.7d 
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Figure B.13. 1HNMR of Compound 3.7e 
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Figure B.14. 13CNMR of Compound 3.7e 
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Figure B.15. 31PNMR of Compound 3.7e 
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Figure B.16. 1HNMR of Compound 3.20 
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Figure B.17. 13CNMR of Compound 3.20 
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Figure B.18. 1HNMR of Compound 3.21 
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Figure B.19. 13CNMR of Compound 3.21 
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Figure B.20. 1HNMR of Compound 3.22 
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Figure B.21. 13CNMR of Compound 3.22 
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Figure B.22. 1HNMR of Compound 3.23 
 
 
 
 
 
 
 
 
 
 
177 
 
Figure B.23. 13CNMR of Compound 3.23 
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Figure B.24. 1HNMR of Compound 3.24 
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Figure B.25. 13CNMR of Compound 3.24 
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Figure B.26. 1HNMR of Compound 3.18a 
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Figure B.27. 13CNMR of Compound 3.18a 
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Figure B.28. 31PNMR of Compound 3.18a 
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Figure B.29. 1HNMR of Compound 3.18b 
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Figure B.30. 13CNMR of Compound 3.18b 
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Figure B.31. 31PNMR of Compound 3.18b 
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Figure B.32. RP HPLC of compound 3.14a 
 
 
Figure B.33. RP HPLC of compound 3.14a 
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Figure B.34. RP HPLC of compound 3.14a 
 
Figure B.35. RP HPLC of compound 3.14a 
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Figure B.36. RP HPLC of compound 3.14b 
 
 
Figure B.37. RP HPLC of compound 3.14b 
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Figure B.38. RP HPLC of compound 3.14b 
 
 
Figure B.39. RP HPLC of compound 3.14b 
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Figure B.40. RP HPLC of compound 3.14c 
 
 
 
Figure B.41. RP HPLC of compound 3.14c 
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Figure B.42. RP HPLC of compound 3.14c 
 
 
Figure B.43. RP HPLC of compound 3.14c 
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Figure B.44. RP HPLC of compound 3.14d 
 
Figure B.45. RP HPLC of compound 3.14d 
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Figure B.46. RP HPLC of compound 3.14d 
 
Figure B.47. RP HPLC of compound 3.14d 
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Figure B.48. RP HPLC of compound 3.14e 
 
 
Figure B.49. RP HPLC of compound 3.14e 
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Figure B.50. RP HPLC of compound 3.14e 
 
Figure B.51. RP HPLC of compound 3.14e 
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Figure B.52. RP HPLC of compound 3.14f 
 
 
Figure B.53. RP HPLC of compound 3.14e 
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Figure B.54. RP HPLC of compound 3.14f 
 
 
 
Figure B.55. RP HPLC of compound 3.14f 
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Figure B.56. RP HPLC of compound 3.14g 
 
Figure B.57. RP HPLC of compound 3.14g 
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Figure B.58. RP HPLC of compound 3.14g 
 
Figure B.59. RP HPLC of compound 3.14g 
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Figure B.60. MALDI-TOF-MS of compound 3.14a 
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Figure B.61. MALDI-TOF-MS of compound 3.14a 
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Figure B.62. MALDI-TOF-MS of compound 3.14b 
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Figure B.63. MALDI-TOF-MS of compound 3.14b 
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Figure B.64. MALDI-TOF-MS of compound 3.14c 
 
 
 
 
 
 
 
 
 
205 
 
Figure B.65. MALDI-TOF-MS of compound 3.14c 
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Figure B.66. MALDI-TOF-MS of compound 3.14d 
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Figure B.67. MALDI-TOF-MS of compound 3.14d 
 
 
 
 
 
 
 
 
 
208 
 
Figure B.68. MALDI-TOF-MS of compound 3.14e 
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Figure B.69. MALDI-TOF-MS of compound 3.14e 
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Figure B.70. MALDI-TOF-MS of compound 3.14f 
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Figure B.71. MALDI-TOF-MS of compound 3.14f 
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Figure B.72. MALDI-TOF-MS of compound 3.14g 
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Figure B.73. MALDI-TOF-MS of compound 3.14g 
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Figure C.1. 1HNMR of Compound 4.10 
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Figure C.2. 13CNMR of Compound 4.10 
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Figure C.3. 1HNMR of Compound 4.11 
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Figure C.4. 13CNMR of Compound 4.11 
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Figure C.5. 1HNMR of Compound 4.12 
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Figure C.6. 13CNMR of Compound 4.12 
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Figure C.7. 1HNMR of Compound 4.3a 
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Figure C.8. 13CNMR of Compound 4.3a 
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Figure C.9. 31PNMR of Compound 4.3a 
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Figure C.10. 1HNMR of Compound 4.16 
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Figure C.11. 13CNMR of Compound 4.16 
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Figure C.12. 1HNMR of Compound 4.17 
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Figure C.13. 13CNMR of Compound 4.17 
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Figure C.14. 1HNMR of Compound 4.18 
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Figure C.15. 13CNMR of Compound 4.18 
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Figure C.16. 1HNMR of Compound 4.3b 
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Figure C.17. 13CNMR of Compound 4.18 
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Figure C.18. 31PNMR of Compound 4.3b 
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Figure C.19. 1HNMR of Compound 4.21 
 
 
 
 
 
 
 
 
 
 
234 
 
Figure C.20. 13CNMR of Compound 4.21 
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Figure C.21. 1HNMR of Compound 4.22 
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Figure C.22. 13CNMR of Compound 4.22 
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Figure C.23. 1HNMR of Compound 4.23 
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Figure C.24. 13CNMR of Compound 4.23 
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Figure C.25. 1HNMR of Compound 4.3c 
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Figure C.26. 13CNMR of Compound 4.3c 
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Figure C.27. 31PNMR of Compound 4.3c 
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Figure C.28. 1HNMR of Compound 4.25 
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Figure C.29. 13CNMR of Compound 4.25 
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Figure C.30. 31PNMR of Compound 4.25 
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Figure C.31. 1HNMR of Compound 4.28 
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Figure C.32. 13CNMR of Compound 4.28 
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Figure C.33. 1HNMR of Compound 4.29 
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Figure C.34. 13CNMR of Compound 4.29 
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Figure C.35. 1HNMR of Compound 4.26a 
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Figure C.36. 13CNMR of Compound 4.26a 
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Figure C.37. 31PNMR of Compound 4.26a 
 
 
 
 
 
Figure C.38. RP HPLC crude trityl-tagged ODN 5'-TTA TCC ACT TCC GTT CTA CT-
3’ (4.30a-tr). The peak at 35-39min corresponds to the trityl-tagged ODN. The peaks 
after 40min correspond to branched sequences. 
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Figure C.39. RP HPLC profile of purified trityl-tagged ODN 5'-TTA TCC ACT TCC 
GTT CTA CT-3' (4.30a-tr).CTA CT-3' (4.30a-tr). 
 
 
 
Figure C.40. RP HPLC profile of de-tritylated ODN 5'-TTA TCC ACT TCC GTT CTA 
CT-3' (4.30a). 
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Figure C.41. RP HPLC profile of pure de-tritylated ODN 5'-TTA TCC ACT TCC GTT 
CTA CT-3' (4.30a). 
 
 
 
 
 
 
 
 
Figure C.42. RP HPLC profile of crude trityl-tagged ODN 5'-TTA TCA AAC TTG TAA 
CCC CT-3' (4.30b-tr). The peak at 35-39 min corresponds to the trityl-tagged ODN. The 
peaks after 40 min correspond to branched sequences. 
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Figure C.43. RP HPLC profile of purified trityl-tagged ODN 5'-TTA TCA AAC TTG 
TAA CCC CT-3' (4.30b-tr). 
 
 
 
 
 
 
 
 
Figure C.44. RP HPLC profile of de-tritylated ODN 5'-TTA TCA AAC TTG TAA CCC 
CT-3' (4.30b). 
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Figure C.45. RP HPLC profile of pure de-tritylated ODN 5'-TTA TCA AAC TTG TAA 
CCC CT-3' (4.30b). 
 
 
 
 
 
 
 
Figure C.46. A typical RP HPLC profile of crude ODN (5'-CTA GAT AAC TCA TAG 
TAC TT-3') synthesized using 4.3a-c and 4.4 under standard conditions using acetic 
anhydride for capping and without 5'-tagging with hydrophobic groups such as trityl and 
DMTr groups. The peak between 19 and 21 min corresponds to the ODN. The peaks after 
21 min correspond to branched sequences. Because the desired ODN and branched 
sequences were very close, ODN purification was difficult. 
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Figure C.47. RP HPLC profile of the crude ODN 5'-DMTr-O-TTC CAT CCT AGA 
AAG CTC AT-3' synthesized using 4.3a-c and 4.4 under standard conditions using acetic 
anhydride for capping. At the end of synthesis, the DMTr group was not removed. 
Although not always possible, in this case, the DMTr protection survived the cleavage 
and deprotection conditions involving sodium periodate. The peak in the profile between 
43 and 45 min corresponds to the DMTr-tagged ODN. The peaks after 47 min correspond 
to branched sequences. The branched sequences have longer retention times because they 
have two or more 5'-ends and thus have two or more DMTr groups.  
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Figure C.48. A typical RP HPLC profile of crude ODN (5'-TBDPS-O-CTA GAT AAC 
TCA TAG TAC TT-3') synthesized using 4.3a-c and 4.4 under standard conditions using 
acetic anhydride for capping and tagged with a TBDPS group at the 5'-end. The TBDPS, 
which is the tBu(Ph2)Si- group, was introduced after solid phase synthesis (5'-DMTr 
group removed) and before cleavage and deprotection by soaking the CPG in 0.1 M 
tBu(Ph2)SiCl and 0.1 M imidazole in DMF (rt, 12 h). Cleavage and deprotection were 
then carried out as described in the article. The peak between 41 and 42 min corresponds 
to the tagged ODN. The peaks after 43 min correspond to branched sequences. The 
branched sequences have longer retention times because they have two or more 5'-ends 
and thus have two or more TBDPS groups. The approach separated the desired ODN 
from the branched sequences very well, but at this stage, we cannot identify a mild 
condition that is compatible with sensitive modifications on ODNs to remove the TBDPS 
group after the ODN is purified. 
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Figure C.49. RP HPLC profile of crude trityl-tagged ODN 4.30c-tr. The peak at 37-40 
min corresponds to the trityl-tagged ODN. The peaks after 40 min correspond to 
branched sequences. 
 
 
Figure C.50. RP HPLC profile of purified trityl-tagged ODN 4.30c-tr. 
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Figure C.51. RP HPLC profile of de-tritylated ODN 4.30c. 
 
 
Figure C.52. RP HPLC profile of purified de-tritylated ODN 4.30c. 
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Figure C.53. RP HPLC profile of crude trityl-tagged ODN 4.30d-tr. The peak at 37-40 
min corresponds to the trityl-tagged ODN. The peaks after 40 min correspond to 
branched sequences. 
 
 
Figure C.54. RP HPLC profile of purified trityl-tagged ODN 4.30d-tr. 
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Figure C.55. RP HPLC profile of de-tritylated ODN 4.30d. 
 
 
 
Figure C.56. RP HPLC profile of purified de-tritylated ODN 4.30d. 
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Figure C.57. RP HPLC profile of crude trityl-tagged ODN 4.30e-tr. The peak at 37-40 
min corresponds to the trityl-tagged ODN. The peaks after 40 min correspond to 
branched sequences. 
 
 
 
Figure C.58. RP HPLC profile of purified trityl-tagged ODN 4.30e-tr. 
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Figure C.58. RP HPLC profile of de-tritylated ODN 4.30e. 
 
Figure C.59. RP HPLC profile of purified de-tritylated ODN 4.30e. 
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Figure C.59. MALDI-TOF-MS of compound 4.30a-tr and 4.30a, respectively 
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Figure C.60. MALDI-TOF-MS of compound 4.30b-tr and 4.30b, respectively 
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Figure C.61. MALDI-TOF-MS of compound 4.30c-tr and 4.30c, respectively 
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Figure C.62. MALDI-TOF-MS of compound 4.30d-tr and 4.30d, respectively 
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Figure C.63. MALDI-TOF-MS of compound 4.30e-tr and 4.30e, respectively 
